var title_f17_22_17760="Transmural balloon dilation";
var content_f17_22_17760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS-guided pancreatic pseudocyst drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image demonstrating balloon dilatation of fistulous tract between gastric wall and the adjacent pseudocyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17760=[""].join("\n");
var outline_f17_22_17760=null;
var title_f17_22_17761="Incision and drainage for breast abscess";
var content_f17_22_17761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incision and drainage for breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large incisions are not necessary to drain breast abscesses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17761=[""].join("\n");
var outline_f17_22_17761=null;
var title_f17_22_17762="Recombination";
var content_f17_22_17762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Recombination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17762=[""].join("\n");
var outline_f17_22_17762=null;
var title_f17_22_17763="Beractant: Drug information";
var content_f17_22_17763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beractant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/18/39202?source=see_link\">",
"    see \"Beractant: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Survanta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Survanta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Lung Surfactant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/18/39202?source=see_link\">",
"      see \"Beractant: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Respiratory distress treatment:",
"     </b>",
"     Premature infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylactic treatment:",
"     </i>",
"     Endotracheal: Administer 4 mL/kg (100 mg phospholipids/kg) as soon as possible; as many as 4 doses may be administered during the first 48 hours of life, no more frequently than 6 hours apart. The need for additional doses is determined by evidence of continuing respiratory distress; if the infant is still intubated and requiring at least 30% inspired oxygen to maintain a PaO",
"     <sub>",
"      2",
"     </sub>",
"     &le;80 torr.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rescue treatment:",
"     </i>",
"     Endotracheal: Administer 4 mL/kg (100 mg phospholipids/kg) as soon as the diagnosis of RDS is made; may repeat if needed, no more frequently than every 6 hours to a maximum of 4 doses",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intratracheal [bovine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Survanta&reg;: Phospholipids 25 mg/mL (4 mL, 8 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      For endotracheal administration only",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suction infant prior to administration. Inspect solution to verify complete mixing of the suspension (may swirl gently, but DO NOT SHAKE). Do not filter dose and avoid shaking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer endotracheally by instillation through a 5-French end-hole catheter inserted into the infant's endotracheal tube.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer the dose in four 1 mL/kg aliquots. Each quarter-dose is instilled over 2-3 seconds followed by at least 30 seconds of manual ventilation or until stable; each quarter-dose is administered with the infant in a different position. Slightly downward inclination with head turned to the right, then repeat with head turned to the left; then slightly upward inclination with head turned to the right, then repeat with head turned to the left. Following administration of one full dose, withhold suctioning for 1 hour unless signs of significant airway obstruction.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of respiratory distress syndrome (RDS) in premature infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Prophylactic therapy: Body weight &lt;1250 g in infants at risk for developing, or with evidence of, surfactant deficiency (administer within 15 minutes of birth)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rescue therapy: Treatment of infants with RDS confirmed by x-ray and requiring mechanical ventilation (administer as soon as possible - within 8 hours of age)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Survanta&reg; may be confused with Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     During the dosing procedure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Cardiovascular: Transient bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Respiratory: Oxygen desaturation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apnea, endotracheal tube blockage, hypercarbia, hyper-/hypotension, post-treatment nosocomial sepsis probability increased, pulmonary air leaks, pulmonary interstitial emphysema, vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10242448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     There are no contraindications listed within the FDA-approved labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transient adverse effects: Transient episodes of bradycardia and decreased oxygen saturation occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For endotracheal administration only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance that may require frequent adjustments to oxygen delivery and ventilator settings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Survanta Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/mL 0.9% (4 mL): $459.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F140408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous ECG and transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation should be monitored during administration; frequent arterial blood gases are necessary to prevent postdosing hyperoxia and hypocarbia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Surfacten (JP);",
"     </li>",
"     <li>",
"      Survanta (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CO, CR, CY, CZ, DE, DO, EC, EG, ES, FR, GB, GR, GT, GY, HK, HN, HU, ID, IE, IL, IQ, IR, JM, JO, KW, LB, LU, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, QA, SA, SG, SR, SV, SY, TH, TT, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Survanta-Vent (SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS) or in neonates at risk of developing RDS. Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Clearance: Alveolar clearance is rapid",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9122 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17763=[""].join("\n");
var outline_f17_22_17763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140419\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140420\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140446\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140433\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682282\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682283\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140398\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140412\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140411\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140451\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140444\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10242448\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140402\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140406\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323016\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140416\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140401\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140414\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/18/39202?source=related_link\">",
"      Beractant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17764="Treatment of interstitial cystitis/bladder pain syndrome";
var content_f17_22_17764=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/22/17764/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17764/contributors\" id=\"au3806\">",
"       J Quentin Clemens, MD, FACS, MSCI",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/22/17764/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17764/contributors\" id=\"se158\">",
"       Michael P O'Leary, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/22/17764/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17764/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/22/17764?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     is a disorder with symptoms of mild to severe bladder pain and an urgent",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     frequent need to urinate. Treatment of",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     often depends upon a clinician's preferences and experience in treating the disorder rather than upon scientific studies because the cause of this condition is not clear.",
"    </p>",
"    <p>",
"     A number of treatments are available for",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     many of which are effective for at least some patients. Most patients with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     need to try more than one treatment, sometimes in combination, to find the one(s) that provides the greatest relief [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     This topic review discusses the treatment of",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"     A separate topic review discusses the symptoms and diagnosis of",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"     (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"      \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AVOIDING PAINFUL BLADDER FLARES",
"     </span>",
"    </p>",
"    <p>",
"     Many people with interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     have periods when symptoms are not bothersome that alternate with periods when symptoms are bothersome or even severe (called flares). It is not always clear why flares develop. However, the following triggers may worsen symptoms in some people:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Certain conditions, such as bladder infections or gastrointestinal problems",
"      </li>",
"      <li>",
"       Certain activities, such as sex and prolonged sitting",
"      </li>",
"      <li>",
"       Foods and beverages, including spicy foods, alcohol and coffee",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Aggravating conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Conditions such as bladder infections and vaginal infections can worsen",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     symptoms and should be evaluated and treated promptly. Because symptoms of these other conditions are often similar to those of",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     most patients should see a healthcare provider to confirm their diagnosis, rather than simply self-treating based upon symptoms. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=see_link\">",
"      \"Patient information: Vaginal yeast infection (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other disorders that cause pain should also be treated since pain in other areas may increase bladder sensitivity. These disorders include inflammatory bowel disease (Crohn's disease, ulcerative colitis, diverticulitis), irritable bowel syndrome, painful menstrual periods, or endometriosis. More than one healthcare provider or specialist is often needed for people who have multiple medical conditions. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"      \"Patient information: Endometriosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Activities",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, exercise or recreational activities (eg, riding a bicycle), sexual activity, or certain body positions (eg, prolonged sitting) can worsen bladder symptoms. Other activities, such as yoga, Pilates, walking, or working at a standing desk may be less bothersome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Foods and beverages",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are able to identify foods or drinks that aggravate bladder pain or urinary urgency or frequency, it is reasonable to avoid these items during a symptom flare. However, it is not clear that these items should be avoided at other times. &nbsp;Some practitioners strongly recommend a highly restrictive \"interstitial cystitis diet\" [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/2\">",
"      2",
"     </a>",
"     ], although its benefit has never been studied.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      COPING WITH CHRONIC PAIN",
"     </span>",
"    </p>",
"    <p>",
"     Interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     is not a psychological disorder, but the symptoms can be worsened by stress, anxiety, depression, and other psychological factors. In addition, living with pain can cause difficulties in relationships, at work or school, and with general day to day living. Psychosocial support can be helpful in dealing with these issues.",
"    </p>",
"    <p>",
"     Depression is common in people with chronic pain, and can interfere with the success of any treatment regimen. Therefore, evaluation and treatment of depression is recommended, if needed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      \"Patient information: Depression in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     There are several types of psychosocial support:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Psychotherapy involves meeting with a psychologist, psychiatrist, or social worker to discuss emotional responses to living with chronic pain, treatment successes or failures,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       personal relationships.",
"      </li>",
"      <li>",
"       Group psychotherapy allows people to compare their experiences with",
"       <span class=\"nowrap\">",
"        IC/BPS,",
"       </span>",
"       overcome the tendency to withdraw and become isolated in pain, and support one another's attempts at more effective management.",
"      </li>",
"      <li>",
"       National support groups are also available, including the Interstitial Cystitis Association (",
"       <a class=\"external\" href=\"file://www.ichelp.org/\">",
"        www.ichelp.org",
"       </a>",
"       ) and the Interstitial Cystitis Network (",
"       <a class=\"external\" href=\"file://www.ic-network.com/\">",
"        www.ic-network.com",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Online or local support groups that deal with chronic pain may also be helpful, such as the American Chronic Pain Society (",
"     <a class=\"external\" href=\"file://www.theacpa.org/\">",
"      www.theacpa.org",
"     </a>",
"     ) and the American Academy of Pain Management (",
"     <a class=\"external\" href=\"file://www.aapainmanage.org/links/Links.php\">",
"      www.aapainmanage.org/links/Links.php",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relaxation techniques can relieve musculoskeletal tension, and may include meditation, progressive muscle relaxation, self-hypnosis, or biofeedback.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BEHAVIORAL THERAPY FOR BLADDER PAIN",
"     </span>",
"    </p>",
"    <p>",
"     Behavioral therapies are treatments that can improve bothersome symptoms through changes in behavior. For people with interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS),",
"     </span>",
"     one of the more bothersome symptoms is the need to frequently urinate. Behavioral therapies for urinary frequency work to slowly increase the time interval between voids, which increases the amount of urine the bladder can comfortably hold; this is called timed voiding.",
"    </p>",
"    <p>",
"     A typical timed voiding protocol involves learning to urinate \"by the clock\" rather than voiding when there is an urge. This is used throughout the day, but is not used while sleeping.",
"    </p>",
"    <p>",
"     As an example, if you currently void every 30 minutes, you will first try to urinate only once every 45 minutes during the daytime, whether you feel the need to urinate or not. You should not urinate more frequently than every 45 minutes, if possible. This voiding goal is continued for a full week or until you are comfortable with this interval.",
"    </p>",
"    <p>",
"     If you are comfortable voiding every 45 minutes, you can increase your time interval by 15 to 30 minutes every week. In this example, you would urinate every 60 minutes for the second week, every 90 minutes for the third week, every 2 hours for the fourth week, and every 2.5 hours for the fifth week.",
"    </p>",
"    <p>",
"     Timed voiding is inexpensive and has no side effects. In one small study of patients with interstitial cystitis, timed voiding significantly reduced symptoms of IC.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PHYSICAL THERAPY FOR PAINFUL BLADDER",
"     </span>",
"    </p>",
"    <p>",
"     Many men and women with interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     have tight and tender muscles and connective tissue in the pelvis, lower abdomen, thighs, groin, and buttocks. Tight muscles and connective tissue can be diagnosed during a physical examination.",
"    </p>",
"    <p>",
"     Pelvic floor physical therapy (PT) may be recommended to decrease tightness in these muscles. PT can decrease bladder or pelvic pain as well as urinary urgency and frequency. This type of PT is quite different from physical therapy intended to treat a knee injury or back pain, which usually works to increase muscle strength. With pelvic floor PT, you lie flat as the physical therapist works on your body to manually \"release\" the tightness, tender points, trigger points, and restricted movement of the connective tissues and muscles. This includes the muscles and tissues of the vagina or rectum, abdomen, hips, thighs, and lower back. Physical therapists who perform this type of PT must be specially trained in pelvic soft tissue manipulation and rehabilitation.",
"    </p>",
"    <p>",
"     Several small studies have demonstrated the benefit of PT for tight and tender pelvic muscles associated with painful bladder",
"     <span class=\"nowrap\">",
"      syndrome/interstitial",
"     </span>",
"     cystitis. One study reported that 70 percent of interstitial cystitis patients who were treated with manual physical therapy to the pelvic floor tissues for 12 to 15 visits experienced moderate to marked improvement [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Pelvic floor PT is usually performed for one hour once per week for at least 12 weeks. You will also be given stretching exercises to perform at home. Most people begin to see improvement after six to eight sessions. If you are not able to tolerate PT due to pain, a local anesthetic can be injected into the painful muscles before PT to reduce pain and allow the therapist to work more effectively.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ORAL MEDICATIONS FOR BLADDER PAIN",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Pentosan polysulfate sodium",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pentosan polysulfate sodium (PPS; Elmiron&reg;) is an oral medication that was developed to repair the lining of the bladder in people with",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"     Studies have shown that this medication is effective in reducing symptoms in some patients with",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     although it rarely causes the symptoms to go away completely. It can take three to six months of treatment before a benefit is observed. Side effects are usually mild, and include hair loss, gastrointestinal symptoms, and increased liver function tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17886116\">",
"     <span class=\"h2\">",
"      Amitriptyline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Amitriptyline (Elavil&reg;) is an antidepressant that is commonly used to treat people with chronic pain problems. When used to treat pain, the dose of amitriptyline is typically much lower than that used for treating depression. It is believed that amitriptyline reduces pain perception when used in low doses, but the exact mechanism of its benefit is unknown. In the United States, amitriptyline is not approved for the treatment of pain caused by",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     although it is safe and effective for the treatment of other pain conditions.",
"    </p>",
"    <p>",
"     Common side effects of amitriptyline are fatigue, dry mouth, weight gain, and a decrease in blood pressure after sitting or standing up. Amitriptyline is generally started at a low dose (5 to 10 mg) and increased gradually. This medicine can cause drowsiness and is usually taken at bedtime. The pain relief benefit may not be seen for three or more weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17886132\">",
"     <span class=\"h2\">",
"      Other medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral antihistamines such as hydroxyzine (Atarax&reg;, Vistaril&reg;) have been used to treat",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     with variable results. The typical dose is 25 to 50 mg at bedtime. This medication can cause drowsiness. Oral pain medications (such as narcotics and antiinflammatory medications) are also utilized, but should be prescribed by a caregiver who has expertise in chronic pain management.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      BLADDER INSTILLATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17886147\">",
"     <span class=\"h2\">",
"      Dimethylsulfoxide (DMSO)",
"     </span>",
"     &nbsp;&mdash;&nbsp;DMSO is a liquid medication that has been approved by the US Food and Drug Administration to treat interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS).",
"     </span>",
"     DMSO is put into the bladder through a temporary catheter, and is held in place for approximately 20 minutes, if possible. These treatments are often given weekly, for six to eight weeks or longer. DMSO can temporarily cause worsened bladder pain, and it is not effective in all patients. It has been used for many years, and is considered to be very safe, with no known long-term side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17886140\">",
"     <span class=\"h2\">",
"      Other bladder instillations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some healthcare providers recommend a combination of medications, which are instilled into the bladder with a catheter, to reduce symptoms of pain. This can be done in a clinician's office, or you can learn to self-administer the treatment at home.",
"    </p>",
"    <p>",
"     The treatment may be used as a single \"rescue\" treatment when symptoms are severe, or as a regularly scheduled treatment (eg, three times per week for a period of weeks). The medications are in a liquid form and are a small amount (about 15 mL or 0.5 ounces). You hold the liquid in the bladder for as long as possible, and then urinate normally.",
"    </p>",
"    <p>",
"     The combination of medications may include lidocaine, heparin, and sodium bicarbonate. It is believed that this combination helps to repair the bladder lining and decrease nerve sensitivity in the bladder.",
"    </p>",
"    <p>",
"     In one small study, approximately 80 percent of patients had decreased pain for at least four hours after one treatment with heparin, sodium bicarbonate, and lidocaine [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/4\">",
"      4",
"     </a>",
"     ]. In addition, some patients experience reduced pain for days or weeks after bladder installations.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      ELECTRICAL STIMULATION FOR PAINFUL BLADDER",
"     </span>",
"    </p>",
"    <p>",
"     If other treatments for interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS)",
"     </span>",
"     fail to improve pain or cannot be tolerated, some clinicians will consider performing a surgical treatment called sacral nerve stimulation. This involves placing a small wire under the skin just above the tailbone. This wire sends a mild electrical pulse to nerves in the area; this pulse is thought to interrupt signals from the brain that trigger pain, urgency, and frequency in people with",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"     Most patients can feel the electrical pulse, although it is not painful and usually becomes less noticeable over time.",
"    </p>",
"    <p>",
"     The treatment is done in two stages. During the first stage, a wire is placed next to the nerve in the low back, then tunneled out of the skin and connected to a small battery (about the size of a pager) that is worn on the waist. The wires are taped securely to the skin. The first-stage procedure can be performed in a doctor&rsquo;s office or as a same-day surgery in the operating room. If your symptoms improve from the stimulation (over a period of days to one week), a permanent battery is attached to the wire, and the battery and wire are then surgically implanted under the skin of the upper buttock (",
"     <a class=\"graphic graphic_figure graphicRef60564 \" href=\"UTD.htm?14/50/15143\">",
"      figure 1",
"     </a>",
"     ). If your symptoms do not improve, the wires and device are removed. This second-stage procedure is performed as same-day surgery in the operating room. &nbsp;",
"    </p>",
"    <p>",
"     Small trials of sacral nerve stimulation show that many people with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     improve significantly after the procedure [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/5\">",
"      5",
"     </a>",
"     ]. However, the surgical procedure and device (called Interstim&trade;) are expensive. Interstim&trade; is not approved by the US Food and Drug Administration for treatment of pain caused by",
"     <span class=\"nowrap\">",
"      IC/BPS,",
"     </span>",
"     although it is approved for treatment of other bladder problems (eg, urinary urgency-frequency, overactive bladder).",
"    </p>",
"    <p>",
"     Risks of the procedure include the need for a subsequent surgery to reposition or remove the wire or pulse generator, infection, bleeding, and pain. Anyone who is considering sacral nerve stimulation should discuss the risks and benefits with a physician who is experienced and knowledgeable about all available treatments for",
"     <span class=\"nowrap\">",
"      IC/BPS.",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17886184\">",
"     <span class=\"h1\">",
"      EXPERIMENTAL THERAPIES",
"     </span>",
"    </p>",
"    <p>",
"     Since no treatment is very effective for patients with interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS),",
"     </span>",
"     researchers continue to develop and test new therapies. While the possibility of new, more effective treatments is exciting, these new treatments may cause dangerous side effects in some patients.",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     patients who are considering experimental treatments should be sure to understand the possible risks involved.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17886176\">",
"     <span class=\"h1\">",
"      SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     Major surgery (such as removal of the bladder) may be performed to treat severe interstitial",
"     <span class=\"nowrap\">",
"      cystitis/bladder",
"     </span>",
"     pain syndrome",
"     <span class=\"nowrap\">",
"      (IC/BPS),",
"     </span>",
"     which has not responded to other therapies. Even with experienced surgeons, these surgeries may be associated with severe, life-threatening complications. Most patients with",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     are not good candidates for major surgery. Furthermore, it is not always guaranteed that these surgeries will relieve",
"     <span class=\"nowrap\">",
"      IC/BPS",
"     </span>",
"     symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784812592\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962125\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/11/20658?source=see_link\">",
"      Patient information: Bladder pain syndrome (interstitial cystitis) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962151\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/53/2899?source=see_link\">",
"      Patient information: Vaginal yeast infection (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8330?source=see_link\">",
"      Pathogenesis, clinical features, and diagnosis of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43369?source=see_link\">",
"      Management of interstitial cystitis/bladder pain syndrome",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information [",
"     <a class=\"abstract\" href=\"UTD.htm?17/22/17764/abstract/3,4\">",
"      3,4",
"     </a>",
"     ]:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/interstitialcystitis/\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/interstitialcystitis/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://womenshealth.gov/publications/our-publications/fact-sheet/interstitial-cystitis.cfm\">",
"      womenshealth.gov/publications/our-publications/fact-sheet/interstitial-cystitis.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Interstitial Cystitis Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ichelp.org/\">",
"      www.ichelp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Interstitial Cystitis Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ic-network.com/\">",
"      www.ic-network.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       European Society for the Study of Interstitial Cystitis",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.essic.eu/\">",
"      www.essic.eu",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Painful Bladder Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.painful-bladder.org/index.html\">",
"      www.painful-bladder.org/index.html",
"     </a>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/22/17764?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17764/abstract/1\">",
"      Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011; 185:2162.",
"     </a>",
"    </li>",
"    <li>",
"     www.ichelp.org/TreatmentAndSelfHelp/ICAndDiet.html (Accessed on January 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17764/abstract/3\">",
"      Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol 2001; 166:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17764/abstract/4\">",
"      Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005; 65:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17764/abstract/5\">",
"      Marinkovic SP, Gillen LM, Marinkovic CM. Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J 2011; 22:407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_22_17764=[""].join("\n");
var outline_f17_22_17764=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AVOIDING PAINFUL BLADDER FLARES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           COPING WITH CHRONIC PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BEHAVIORAL THERAPY FOR BLADDER PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PHYSICAL THERAPY FOR PAINFUL BLADDER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ORAL MEDICATIONS FOR BLADDER PAIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           BLADDER INSTILLATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           ELECTRICAL STIMULATION FOR PAINFUL BLADDER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17886184\">",
"           EXPERIMENTAL THERAPIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17886176\">",
"           SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/50/15143\" title=\"figure 1\">",
"           Sacral neuromodulation PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17765="Laparoscopy anatomy";
var content_f17_22_17765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Laparoscopy anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of the abdomen with the patient in Trendelenburg position. The laparoscope (right) is inserted through the umbilicus. Note the proximity of the umbilicus to the sacral promontory (anterior to which pass the aorta and vena cava, not shown here) and the intestines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smeltzer, SC, Bare, BG. Textbook of Medical-Surgical Nursing, 9th Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2000. Copyright &copy;2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17765=[""].join("\n");
var outline_f17_22_17765=null;
var title_f17_22_17766="Discoid lupus scalp";
var content_f17_22_17766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Discoid lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follicular plugging is evident in this patient with discoid lupus erythematosus involving the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Messenger A. Varieties of scarring alopecia. Dermatology In Practice 2003; 11:20. Copyright &copy; Hayward Medical Communications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17766=[""].join("\n");
var outline_f17_22_17766=null;
var title_f17_22_17767="Spironolactone: Drug information";
var content_f17_22_17767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Spironolactone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=see_link\">",
"    see \"Spironolactone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"    see \"Spironolactone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactone&reg;;",
"     </li>",
"     <li>",
"      Novo-Spiroton;",
"     </li>",
"     <li>",
"      Teva-Spironolactone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Potassium Sparing;",
"     </li>",
"     <li>",
"      Selective Aldosterone Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reduce delay in onset of effect, a loading dose of 2 or 3 times the daily dose may be administered on the first day of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Edema:",
"     </b>",
"     Oral: 25-200 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypokalemia:",
"     </b>",
"     Oral: 25-100 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension (JNC 7):",
"     </b>",
"     Oral: 25-50 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnosis of primary aldosteronism:",
"     </b>",
"     Oral: Long test: 400 mg daily for 3-4 weeks; short test: 400 mg daily for 4 days; maintenance until surgical correction: 100-400 mg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure, severe (NYHA class III-IV; with ACE inhibitor and a loop diuretic &plusmn; digoxin):",
"     </b>",
"     12.5-25 mg/day; maximum daily dose: 50 mg. If 25 mg once daily not tolerated, reduce to 25 mg every other day was the lowest maintenance dose possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If potassium &gt;5 mEq/L or serum creatinine &gt;4 mg/dL, discontinue or interrupt therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne in women (unlabeled use):",
"     </b>",
"     Oral: 25-200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hirsutism in women (unlabeled use):",
"     </b>",
"     Oral: 50-200 mg/day in 1-2 divided doses (Koulouri, 2008; Martin, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F222886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"      see \"Spironolactone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food increases absorption. To reduce delay in onset of effect, a loading dose of 2 or 3 times the daily dose may be administered on the first day of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Edema, hypertension (unlabeled use):",
"     </b>",
"     Oral: Children 1-17 years: Initial: 1 mg/kg/day divided every 12-24 hours (maximum dose: 3.3 mg/kg/day, up to 100 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diagnosis of primary aldosteronism (unlabeled use):",
"     </b>",
"     Oral: 125-375 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Indication specific: Initial: 25-50 mg/day in 1-2 divided doses; increase by 25-50 mg every 5 days as needed. Adjust for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F222868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute: Decrease initial dose to 12.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldactone&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aldactone&reg;: 50 mg, 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with excessive aldosterone excretion; hypertension; primary hyperaldosteronism; hypokalemia; cirrhosis of liver accompanied by edema or ascites; nephrotic syndrome; severe heart failure (NYHA class III-IV) to increase survival and reduce hospitalization when added to standard therapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F222905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Female acne (adjunctive therapy); hirsutism; hypertension (pediatric); diuretic (pediatric)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldactone&reg; may be confused with Aldactazide&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aldactone: Brand name for spironolactone [U.S., Canada, multiple international markets], but also the brand name for potassium canrenoate [Austria, Czech Republic, Germany, Hungary, Poland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, drowsiness, fever, headache, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Drug rash with eosinophilia and systemic symptoms (DRESS), maculopapular or erythematous cutaneous eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, gynecomastia, hyperkalemia, impotence, irregular menses, postmenopausal bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Cramps, diarrhea, gastritis, gastric bleeding, nausea, ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic/hepatocellular toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, renal dysfunction, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anuria; acute renal insufficiency; significant impairment of renal excretory function; hyperkalemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecomastia: Related to dose and duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumorigenic:",
"     <b>",
"      [U.S. Boxed Warning]: Shown to be a tumorigen in chronic toxicity animal studies. Avoid unnecessary use.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal vein catheterization: Discontinue use prior to adrenal vein catheterization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: When evaluating a heart failure patient for spironolactone treatment, creatinine should be &le;2.5 mg/dL in men or &le;2 mg/dL in women and potassium &lt;5 mEq/L. Serum potassium levels require close monitoring and management if elevated.  Discontinue or interrupt therapy if serum potassium &gt;5 mEq/L or serum creatinine &gt;4 mg/dL. Avoid concurrent use of ACEIs, ARBs, and spironolactone (Hunt, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium supplements: Avoid potassium supplements, potassium-containing salt substitutes, a diet rich in potassium, or other drugs that can cause hyperkalemia (eg, other potassium-sparing diuretics, NSAIDS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of doses &gt;25 mg/day in patients with heart failure or in patients with reduced renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); risk of hyperkalemia is increased for heart failure patients receiving &gt;25 mg/day, particularly if taking concomitant medications such as NSAIDS, ACE inhibitor, angiotensin receptor blocker, or potassium supplements (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane.  Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F222856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Increases risk of orthostasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food increases absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid natural licorice (due to mineralocorticoid activity)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however, doses used were less than or equal to equivalent doses in humans. The antiandrogen effects of spironolactone have been shown to cause feminization of the male fetus in animal studies. Two case reports did not demonstrate this effect in humans however, the authors caution that adequate data is lacking. Use of diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F222871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F222847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The active metabolite of spironolactone has been found in breast milk. Effects to humans are not known; however, this metabolite was found to be carcinogenic in rats. The manufacturer recommends discontinuing spironolactone or using an alternative method of feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F222848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food to decrease gastrointestinal irritation and to increase absorption. Excessive potassium intake (eg, salt substitutes, low-salt foods, bananas, nuts) should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F222845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aldactone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $138.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $243.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $407.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Spironolactone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $45.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $81.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $142.43",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum electrolytes (potassium, sodium), renal function, I &amp; O ratios and daily weight throughout therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HF: Potassium levels and renal function should be checked in 3 days and 1 week after initiation or increase in dose, then every 2-4 weeks for 3 months, then quarterly for a year, then every 6 months thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F222849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactin (TW);",
"     </li>",
"     <li>",
"      Aldacton (TR);",
"     </li>",
"     <li>",
"      Aldactone (AE, AT, AU, BE, BF, BH, BJ, BR, CH, CI, CO, CR, CY, DE, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, IE, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PA, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Aldactone A (AR, BB, BM, BS, BZ, EC, ES, GY, JM, SR, TT, UY);",
"     </li>",
"     <li>",
"      Aldospirone (IL);",
"     </li>",
"     <li>",
"      Aldoxol (PY);",
"     </li>",
"     <li>",
"      Alizar (CN);",
"     </li>",
"     <li>",
"      Altone (TH);",
"     </li>",
"     <li>",
"      Flumach (FR);",
"     </li>",
"     <li>",
"      Huma-Spiroton (HU);",
"     </li>",
"     <li>",
"      Hyles (TH);",
"     </li>",
"     <li>",
"      Osiren (AT);",
"     </li>",
"     <li>",
"      Osyrol (DE, JP);",
"     </li>",
"     <li>",
"      Pondactone (TH);",
"     </li>",
"     <li>",
"      Skyton (TW);",
"     </li>",
"     <li>",
"      Spiractin (AU, ZA);",
"     </li>",
"     <li>",
"      Spirix (DK, FI, NO);",
"     </li>",
"     <li>",
"      Spiroctan (FR, LU);",
"     </li>",
"     <li>",
"      Spirola (ID);",
"     </li>",
"     <li>",
"      Spirolacton (ID);",
"     </li>",
"     <li>",
"      Spirolon (BF, BJ, CI, EC, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Spiron (DK, HU);",
"     </li>",
"     <li>",
"      Spirone (PE);",
"     </li>",
"     <li>",
"      Spirono-Isis (DE);",
"     </li>",
"     <li>",
"      Spironol (IL);",
"     </li>",
"     <li>",
"      Spironolacton-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Spironolactone-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Spironolactone-Searle (LU);",
"     </li>",
"     <li>",
"      Spirotone (NZ);",
"     </li>",
"     <li>",
"      Unilactone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Uractone (LU);",
"     </li>",
"     <li>",
"      Uractonum (SG);",
"     </li>",
"     <li>",
"      Verospiron (BG, CZ, EE, HN, HU);",
"     </li>",
"     <li>",
"      Vivitar (GT, MX, SV);",
"     </li>",
"     <li>",
"      Xenalon Lactabs (DO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F222841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 91% to 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to multiple metabolites, including active metabolites canrenone and 7-alpha-spirolactone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Spironolactone: 78-84 minutes; Canrenone: 10-23 hours; 7-alpha-spirolactone: 7-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-4 hours (primarily as the active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrilleaux PS and Martin Jr JN, &ldquo;Hypertension Therapy During Pregnancy,&rdquo;",
"      <i>",
"       Clin Obstet Gynecol",
"      </i>",
"      , 2002, 45(1):22-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/11862056/pubmed\" id=\"11862056\" target=\"_blank\">",
"        11862056",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bozkurt B, Agoston I, and Knowlton AA, &ldquo;Complications of Inappropriate Use of Spironolactone in Heart Failure: When an Old Medicine Spirals Out of New Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(2):211-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/12535810/pubmed\" id=\"12535810\" target=\"_blank\">",
"        12535810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Groves TD and Corenblum B, &ldquo;Spironolactone Therapy During Human Pregnancy,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1995, 172(5):1655-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/7755100/pubmed\" id=\"7755100\" target=\"_blank\">",
"        7755100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunter MH and Carek PJ, &ldquo;Evaluation and Treatment of Women With Hirsutism,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 2003, 67(12):2565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/12825846/pubmed\" id=\"12825846\" target=\"_blank\">",
"        12825846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juurlink DN, Mamdani MM, Lee DS, et al, &ldquo;Rates of Hyperkalemia After Publication of the Randomized Aldactone Evaluation Study,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(6):543-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/15295047/pubmed\" id=\"15295047\" target=\"_blank\">",
"        15295047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koulouri O and Conway GS, &ldquo;A Systematic Review of Commonly Used Medical Treatments for Hirsutism in Women,&rdquo;",
"      <i>",
"       Clin Endocrinol",
"      </i>",
"      , 2008, 68(5): 800-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/17980017/pubmed\" id=\"17980017\" target=\"_blank\">",
"        17980017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin KA, Chang RJ, Ehrmann DA, et al, &ldquo;Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(4):1105-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/18252793/pubmed\" id=\"18252793\" target=\"_blank\">",
"        18252793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmer BF, &ldquo;Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351:585-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/15295051/pubmed\" id=\"15295051\" target=\"_blank\">",
"        15295051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Zannad F, Remme WJ, et al, &ldquo;The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(10):709-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/10471456/pubmed\" id=\"10471456\" target=\"_blank\">",
"        10471456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2000, 183(1):S1-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/10920346/pubmed\" id=\"10920346\" target=\"_blank\">",
"        10920346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rigo J Jr, Glaz E, and Papp Z, &ldquo;Low or High Doses of Spironolactone for Treatment of Maternal Bartter's Syndrome,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1996, 174(1 Pt 1):297.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/8572029/pubmed\" id=\"8572029\" target=\"_blank\">",
"        8572029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Runyon BA, &ldquo;Management of Adult Patients With Ascites Due to Cirrhosis: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(6):2087-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/19475696/pubmed\" id=\"19475696\" target=\"_blank\">",
"        19475696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaw JC, &ldquo;Acne: Effect of Hormones on Pathogenesis and Management,&rdquo;",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2002, 3(8):571-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/12358558/pubmed\" id=\"12358558\" target=\"_blank\">",
"        12358558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thiboutot D and Chen W, &ldquo;Update and Future of Hormonal Therapy in Acne,&rdquo;",
"      <i>",
"       Dermatology",
"      </i>",
"      , 2003, 206(1):57-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/22/17767/abstract-text/12566806/pubmed\" id=\"12566806\" target=\"_blank\">",
"        12566806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9943 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17767=[""].join("\n");
var outline_f17_22_17767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709416\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222908\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222866\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222886\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222867\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222868\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222819\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222838\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222905\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222916\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222906\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222842\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222823\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300079\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222828\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222856\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222846\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222871\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222847\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222848\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222845\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222833\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222849\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222822\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222841\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/27/19893?source=related_link\">",
"      Spironolactone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=related_link\">",
"      Spironolactone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17768="Etiology and clinical manifestations of renal tubular acidosis in infants and children";
var content_f17_22_17768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17768/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17768/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17768/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/22/17768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, renal tubular acidosis (RTA) is due to either an inherited or acquired defect that affects the kidney's ability to absorb filtered bicarbonate, or excrete ammonia or titratable acid. RTA is characterized by a normal anion gap (hyperchloremic) metabolic acidosis caused by the net retention of hydrogen or loss of bicarbonate.",
"   </p>",
"   <p>",
"    There are four subgroups of RTA (",
"    <a class=\"graphic graphic_table graphicRef58428 \" href=\"UTD.htm?22/42/23211\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal (type 1) RTA",
"     </li>",
"     <li>",
"      Proximal (type 2) RTA",
"     </li>",
"     <li>",
"      Mixed (type 3) RTA",
"     </li>",
"     <li>",
"      Hypoaldosteronism (type 4 RTA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common pediatric forms of RTA are types 1 and 2.",
"   </p>",
"   <p>",
"    The etiology and clinical manifestations of the different forms of RTA in infants and children will be reviewed here.",
"   </p>",
"   <p>",
"    Other topics review the following aspects of RTA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"       \"Causes and evaluation of hyperkalemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pathophysiology (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link\">",
"       \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISTAL (TYPE 1) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 (distal) RTA is due to impaired distal acid secretion that results in an inability to excrete the daily acid load. In the absence of alkali therapy, progressive hydrogen ion retention leads to a fall in plasma bicarbonate therapy that is accompanied by an abnormally high urine pH (greater than 5.5) (",
"    <a class=\"graphic graphic_table graphicRef58428 \" href=\"UTD.htm?22/42/23211\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of distal RTA in children can be divided into genetic and acquired disorders (",
"    <a class=\"graphic graphic_table graphicRef56437 \" href=\"UTD.htm?17/48/18188\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic primary causes of distal RTA include mutations of genes that encode the chloride-bicarbonate exchanger (AE1) or subunits of the H-ATPase pump (",
"    <a class=\"graphic graphic_table graphicRef59008 \" href=\"UTD.htm?24/21/24924\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dominant distal RTA &mdash; Mutations of the SLC4A1 gene located on chromosome 17q21-q22, which encodes the chloride-bicarbonate exchanger (AE1 or band 3), have been described in several families with autosomal dominant distal RTA [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. Patients with dominant distal RTA generally have milder acidosis than those with recessive disease and present later in life, often in adolescence or adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/5\">",
"       5",
"      </a>",
"      ]. Untreated patients have metabolic acidosis that is associated with hypercalciuria, nephrolithiasis or nephrocalcinosis, osteomalacia, and erythrocytosis. Mutations of the SLC4A1 gene also are reported in some patients with hereditary spherocytosis and southeast Asian ovalocytosis, both of which can be associated with RTA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Band 3 defects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=see_link&amp;anchor=H9#H9\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\", section on 'Southeast Asian ovalocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recessive distal RTA with deafness &mdash; Patients with mutations in the gene ATP6V1B1, which encodes the B1 subunit of H-ATPase, have distal RTA and sensorineural deafness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. This gene is expressed in the intercalated cells of the distal renal tubule, cochlea, and male genital tract, and is located on chromosome 2p13 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. Untreated patients develop severe metabolic acidosis with poor growth, rickets, and nephrocalcinosis during infancy and early childhood. Patients also may develop progressive bilateral sensorineural hearing loss that typically begins in infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/10\">",
"       10",
"      </a>",
"      ]. Treatment of acidosis prevents poor growth, rickets, and nephrocalcinosis but does not improve or prevent ongoing hearing loss.",
"     </li>",
"     <li>",
"      Recessive distal RTA without deafness &mdash; Patients with mutations in the gene ATP6V0A4 located on chromosome 7q33-q34, which encodes the a4 subunit of H-ATPase, develop distal RTA without early hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/11\">",
"       11",
"      </a>",
"      ]. The severity of metabolic acidosis and its associated findings of failure to thrive, rickets, and nephrocalcinosis are similar to that seen in patients with mutations that affect the B1 subunit. This gene product is also expressed in the inner ear, children with mutations of the a4 subunit have normal hearing based upon audiometric screening. However, mild hearing loss may develop in some adult patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic disorders that cause secondary distal RTA include Ehlers-Danlos syndrome and sickle cell anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H10#H10\">",
"     \"Renal manifestations of sickle cell disease\", section on 'Renal tubular acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acquired causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acquired causes of distal RTA in children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications &mdash; The administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      can result in reversible distal RTA. However, the use of lipid formulations of amphotericin B avoids tubular damage and RTA.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"       Lithium",
"      </a>",
"      can cause an incomplete distal RTA with impairment of urine acidification but typically does not cause metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link&amp;anchor=H8#H8\">",
"       \"Amphotericin B nephrotoxicity\", section on 'Electrolyte disorders'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link&amp;anchor=H4#H4\">",
"       \"Renal toxicity of lithium\", section on 'Renal tubular acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune disorders &mdash; Although rare in children, reported autoimmune conditions associated with distal RTA include Sj&ouml;gren syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/13\">",
"       13",
"      </a>",
"      ] and systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link&amp;anchor=H3#H3\">",
"       \"Renal disease in Sj&ouml;gren's syndrome\", section on 'Distal renal tubular acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive uropathy &mdash; Distal RTA may be present in patients with obstructive uropathy due to diminished sodium reabsorption by the principal cells of the distal renal tubule. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Diminished sodium reabsorption in the adjacent principal cells'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of distal RTA vary depending upon the underlying etiology. The recessive forms present in infancy, the dominant form later in life, and acquired distal RTA may occur at any age based upon the timing of renal tubular injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Recessive form",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, the recessive genetic form of RTA usually presents during infancy and generally is associated with severe clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/16\">",
"     16",
"    </a>",
"    ]. These findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe hyperchloremic metabolic acidosis (serum bicarbonate levels may decrease below 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Moderate to severe hypokalemia (serum potassium &le; 3.0",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Nephrocalcinosis",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Poor growth",
"     </li>",
"     <li>",
"      Rickets",
"     </li>",
"     <li>",
"      Bilateral sensorineural hearing loss in some cases with mutations of the gene that encodes B1 subunit of the H-ATPase pump (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic causes'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dominant form",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison with recessive distal RTA, dominant distal RTA is usually associated with milder disease, and presents later in life (often in adolescence and adulthood). The most common initial finding is renal stone or nephrocalcinosis. Patients typically have mild or no acidosis, mild to moderate hypokalemia, and rarely bone disease or poor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of dominant distal RTA were illustrated in a study of 18 patients from four families [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/1\">",
"     1",
"    </a>",
"    ]. Ten patients had mild acidosis with serum bicarbonate levels that ranged from 15 to 21",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The remaining eight patients had impaired urinary acidification, but were not acidotic (serum bicarbonate level &ge; 22",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    These patients were diagnosed with incomplete distal RTA. All patients with complete RTA had either renal stones or nephrocalcinosis. Only one patient had rickets; the rest of the cases had no evidence of bone disease. Twelve patients had normal serum potassium levels, five had",
"    <span class=\"nowrap\">",
"     mild/moderate",
"    </span>",
"    hypokalemia (serum potassium levels between 3.0 to 3.4",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and one patient had severe hypokalemia (serum potassium of 2.1",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Incomplete distal RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROXIMAL (TYPE 2) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal RTA is caused by a reduction in proximal bicarbonate reabsorptive capacity resulting in a fall in the plasma bicarbonate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H42786907#H42786907\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal RTA may present either as an isolated tubular defect or as a component of a generalized proximal tubular disorder called the Fanconi syndrome (",
"    <a class=\"graphic graphic_table graphicRef68165 \" href=\"UTD.htm?22/4/22604\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Isolated proximal RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, isolated proximal RTA is rare. It is usually due to an inherited (",
"    <a class=\"graphic graphic_table graphicRef59008 \" href=\"UTD.htm?24/21/24924\">",
"     table 3",
"    </a>",
"    ) or transient disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient or sporadic proximal RTA &mdash; Infants with transient or sporadic proximal RTA have a decreased capacity to bind bicarbonate without any identifiable cause or evidence of renal abnormality. These infants who are beyond the newborn period are believed to have extended functional immaturity of the proximal sodium-hydrogen exchanger (or antiporter), resulting in an age-based decrease in bicarbonate reabsorption capacity. This reduced capacity, which is the same as that of a normal neonate, results in a persistently low serum bicarbonate level [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients usually present within the first year of life with symptoms of tachypnea, growth failure, recurrent vomiting, and feeding difficulties [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Bone disease, hypokalemia, and urinary concentration defects are uncommon, and hypercalciuria, nephrocalcinosis, and urolithiasis do not occur. Resolution of symptoms and a rapid increase in growth are seen with alkali therapy, which can be discontinued after several years without recurrence of RTA and its symptoms.",
"     </li>",
"     <li>",
"      Autosomal recessive proximal RTA &mdash; Mutations in the gene SLC4A4, which encodes the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      cotransporter (NBC), are associated with isolated proximal RTA [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. This rare disorder with reported cases from Europe and Japan presents with severe hypokalemic, hyperchloremic, metabolic acidosis, growth retardation, and ocular abnormalities including glaucoma, cataracts, and band keratopathy. Ocular findings may progress with age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/21,23\">",
"       21,23",
"      </a>",
"      ]. Additional features include enamel defects of the permanent teeth, impaired psychomotor and cognitive function, and opacification of the basal ganglia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autosomal dominant proximal RTA &mdash; Case reports have described a rare autosomal dominant inheritance pattern of proximal RTA in two families with several affected members [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. In both these families, clinical manifestations were limited to short stature and metabolic acidosis. There was no evidence of bone disease or hypercalciuria. No mutation was found in any of the nine tested candidate genes studied in the Israeli pedigree [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies using a knockout mouse model identified the gene SLC9A3 as a candidate gene for dominant proximal RTA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/28\">",
"     28",
"    </a>",
"    ]. It encodes one of the five plasma membrane sodium-hydrogen exchangers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fanconi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized proximal tubular dysfunction, referred to as Fanconi syndrome, is characterized by hypophosphatemia due to phosphaturia, renal glucosuria (glucosuria with a normal plasma glucose concentration), aminoaciduria, tubular proteinuria, and proximal RTA.",
"   </p>",
"   <p>",
"    The etiology of Fanconi syndrome includes inherited diseases or acquired causes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic conditions associated with Fanconi syndrome include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dents disease (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link&amp;anchor=H7#H7\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\", section on 'Proximal tubular reabsorptive failure and proteinuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystinosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link&amp;anchor=H8#H8\">",
"       \"Cystinosis\", section on 'Renal symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tyrosinemia type 1 (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H4#H4\">",
"       \"Disorders of tyrosine metabolism\", section on 'Hereditary tyrosinemia type 1'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Galactosemia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of galactosemia\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wilson disease (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500456#H69500456\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Other manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lowe oculocerebrorenal syndrome (MIM #30900), also referred to as Lowe syndrome (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link&amp;anchor=H4#H4\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\", section on 'OCRL1 gene and the Lowe oculocerebrorenal syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hereditary fructose intolerance",
"     </li>",
"     <li>",
"      Mitochondrial myopathies (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal involvement in the mitochondrial cytopathies\", section on 'Tubular disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired causes of Fanconi syndrome include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Drugs &mdash; Medication associated with Fanconi syndrome include aminoglycosides,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34949?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"       ifosfamide",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link&amp;anchor=H5#H5\">",
"       \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\", section on 'Electrolyte abnormalities'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=see_link&amp;anchor=H3#H3\">",
"       \"Ifosfamide nephrotoxicity\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link&amp;anchor=H11#H11\">",
"       \"Cisplatin nephrotoxicity\", section on 'Fanconi-like syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heavy metals &mdash; Heavy metals associated with Fanconi syndrome include lead, mercury, and cadmium (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24760?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and toxicity of cadmium\", section on 'Tubular damage and dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link&amp;anchor=H14#H14\">",
"       \"Epidemiology and toxicity of mercury\", section on 'Tubular dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link&amp;anchor=H6#H6\">",
"       \"Lead nephropathy and lead-related nephrotoxicity\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations associated with proximal RTA vary depending upon whether the tubular acidosis is an isolated finding or is a part of the Fanconi syndrome.",
"   </p>",
"   <p>",
"    The clinical manifestations of the rare causes of isolated proximal RTA are discussed previously. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Isolated proximal RTA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical findings of Fanconi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with Fanconi syndrome, the age of presentation varies with the underlying etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several genetic causes of Fanconi appear during infancy, including Lowe oculocerebrorenal syndrome, the infantile form of cystinosis, and Dent disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link&amp;anchor=H7#H7\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\", section on 'Proximal tubular reabsorptive failure and proteinuria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link&amp;anchor=H4#H4\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\", section on 'OCRL1 gene and the Lowe oculocerebrorenal syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link&amp;anchor=H4#H4\">",
"       \"Cystinosis\", section on 'Infantile form'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other genetic conditions, such as Wilson disease, late-onset forms of cystinosis, and galactosemia present with Fanconi syndrome later in life as accumulation of toxic material (eg, copper in Wilson disease) over time results in progressive proximal renal tubular damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of galactosemia\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystinosis\", section on 'Intermediate and adult cystinosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69500456#H69500456\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Other manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acquired Fanconi may occur at any age depending upon the timing of exposure to noxious toxins and drugs, which injure the proximal tubule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, the most common clinical findings of Fanconi syndrome are growth failure, and episodes of hypovolemia due to polyuria caused by impaired concentrating ability. Poor growth may be due to hypophosphatemia, persistent acidosis, chronic hypokalemia, rickets, and volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/29\">",
"     29",
"    </a>",
"    ]. Other findings may include bony abnormalities, including rickets and osteomalacia due to hypophosphatemia and low levels of calcitriol (1,25 dihydroxy vitamin D), and constipation and muscle weakness caused by significant hypokalemia (serum potassium less than 3",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3819896#H3819896\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Severe muscle weakness or rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory evaluation demonstrates hyperchloremic metabolic acidosis, hypophosphatemia, moderate to severe hypokalemia (serum potassium levels less than 3",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    and proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MIXED (TYPE 3) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 RTA, also referred to as mixed RTA, is a rare autosomal recessive disorder that has features of both distal and proximal RTA. It is due to an inherited carbonic anhydrase (CA) II deficiency.",
"   </p>",
"   <p>",
"    Because CA II is widely expressed, mutations of the CA II gene (located on chromosome 8q22) result in a syndrome with multiple clinical findings, including mixed RTA, osteopetrosis, cerebral calcification, and mental retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. This constellation of findings is also referred to as Guibaud-Vainsel syndrome or marble brain disease. Other clinical features include bone fractures (due to increased bone fragility) and growth failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/34\">",
"     34",
"    </a>",
"    ]. Excessive facial bone growth leads to facial dysmorphism, and conductive hearing loss and blindness due to nerve compression. The majority of affected patients are of Arabic descent and live in North Africa and the Middle East.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HYPOALDOSTERONISM (TYPE 4 RTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoaldosteronism is uncommon in children. It is due to either aldosterone deficiency or tubular resistance to the action of aldosterone (ie, mineralocorticoid deficiency). Because aldosterone is the major hormone that promotes potassium excretion, hypoaldosteronism is typically characterized by hyperkalemia and mild acidosis (serum bicarbonate above 17",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    Other clinical features in children with hypoaldosteronism may include failure to thrive and hyponatremia because of sodium loss.",
"   </p>",
"   <p>",
"    Unlike adults in whom the most common causes of hypoaldosteronism are diabetic neuropathy or chronic interstitial nephritis, hypoaldosteronism in children is more likely to be due to drugs that impair aldosterone release or function (",
"    <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"     table 5",
"    </a>",
"    ). These include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , nonsteroidal antiinflammatory agents, angiotensin inhibitors,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , calcineurin inhibitors (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), and potassium sparing diuretics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/0/17414?source=see_link\">",
"     spironolactone",
"    </a>",
"    ). In addition, HIV infection is also associated with hypoaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17768/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, Hypoaldosteronism due to inherited disorders include the following rare disorders, which are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Disorders of steroidogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital adrenal insufficiency",
"     </li>",
"     <li>",
"      Aldosterone synthase deficiency",
"     </li>",
"     <li>",
"      Pseudohypoaldosteronism distal and 2 (also known as Gordon syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal tubular acidosis (RTA) is due to either an inherited or acquired renal tubular defect that affects the kidney's ability to absorb filtered bicarbonate, or excrete ammonia or titratable acid. It is characterized by a normal anion gap (hyperchloremic) metabolic acidosis caused by the net retention of hydrogen or the net loss of bicarbonate.",
"   </p>",
"   <p>",
"    There are four subgroups of RTA. The most common pediatric forms are distal (distal) RTA and proximal (proximal) RTA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal (type 1) RTA is due to impaired distal acid secretion that results in an inability to excrete the daily acid load. It is divided into genetic causes due to mutations of genes that encode the chloride-bicarbonate exchanger (AE1) or subunits of the H-ATPase pump, and acquired causes due to distal tubular injury from drugs, autoimmune disorders, or obstructive uropathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical manifestations of distal RTA are dependent upon the underlying etiology. Recessive autosomal distal RTA generally presents in infancy and is associated with more severe disease than the dominant form, which presents later in life. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal (type 2) RTA is caused by a reduction in proximal renal tubular bicarbonate reabsorptive capacity, resulting in a fall in the plasma bicarbonate. Its etiology is divided into disorders with isolated RTA and those with generalized proximal tubular dysfunction, referred to as Fanconi syndrome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children, isolated proximal RTA is rare and is usually due to an inherited or transient disorder. Clinical features vary with the underlying etiology. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Isolated proximal RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fanconi syndrome is the most common cause of proximal RTA in children and is caused by inherited diseases (eg, Dents disease and cystinosis) and acquired disorders (eg, heavy metal toxicity and drugs). It is characterized by phosphaturia resulting in hypophosphatemia, renal glucosuria, aminoaciduria, tubular proteinuria, and proximal RTA. The age of clinical presentation depends upon the underlying etiology. Clinical findings include growth failure, hypovolemia, bony abnormalities (eg, rickets and osteomalacia), and constipation and muscle weakness due to hypokalemia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fanconi syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical findings of Fanconi syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mixed (type 3) RTA is a rare autosomal recessive disorder that has features of both types 1 and 2 RTA. It is due to an inherited carbonic anhydrase (CA) II deficiency. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mixed (type 3) RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoaldosteronism (type 4 RTA) is due to either aldosterone deficiency or tubular resistance to the action of aldosterone. It is uncommon in children and is generally characterized by hyperkalemia and mild acidosis (serum bicarbonate above 17",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      In children, the most common cause of hypoaldosteronism is drugs (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      , nonsteroidal antiinflammatory agents, angiotensin inhibitors,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/8/5255?source=see_link\">",
"       trimethoprim",
"      </a>",
"      , calcineurin inhibitors, and potassium sparing diuretics) that impair aldosterone release or function. HIV may also be associated with hypoaldosteronism. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hypoaldosteronism (type 4 RTA)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/1\">",
"      Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/2\">",
"      Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem 1998; 273:6380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/3\">",
"      Karet FE, Gainza FJ, Gy&ouml;ry AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 1998; 95:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/4\">",
"      Hu PY, Roth DE, Skaggs LA, et al. A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. Hum Mutat 1992; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/5\">",
"      Agroyannis B, Koutsikos D, Tzanatos-Exarchou H, Yatzidis H. Erythrocytosis in type I renal tubular acidosis with nephrocalcinosis. Nephrol Dial Transplant 1992; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/6\">",
"      Royer P, Broyer M, Nordmann Y. [Enzymatic anomalies and human nephropathies]. Pathol Biol 1967; 15:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/7\">",
"      Karet FE, Finberg KE, Nelson RD, et al. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/8\">",
"      Sterkers O, Saumon G, Tran Ba Huy P, et al. Electrochemical heterogeneity of the cochlear endolymph: effect of acetazolamide. Am J Physiol 1984; 246:F47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/9\">",
"      Herak-Kramberger CM, Breton S, Brown D, et al. Distribution of the vacuolar H+ atpase along the rat and human male reproductive tract. Biol Reprod 2001; 64:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/10\">",
"      Joshua B, Kaplan DM, Raveh E, et al. Audiometric and imaging characteristics of distal renal tubular acidosis and deafness. J Laryngol Otol 2008; 122:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/11\">",
"      Karet FE, Finberg KE, Nayir A, et al. Localization of a gene for autosomal recessive distal renal tubular acidosis with normal hearing (rdRTA2) to 7q33-34. Am J Hum Genet 1999; 65:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/12\">",
"      Stover EH, Borthwick KJ, Bavalia C, et al. Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence for hearing loss. J Med Genet 2002; 39:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/13\">",
"      Pessler F, Emery H, Dai L, et al. The spectrum of renal tubular acidosis in paediatric Sj&ouml;gren syndrome. Rheumatology (Oxford) 2006; 45:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/14\">",
"      Hataya H, Ikeda M, Ide Y, et al. Distal tubular dysfunction in lupus nephritis of childhood and adolescence. Pediatr Nephrol 1999; 13:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/15\">",
"      Bagga A, Jain Y, Srivastava RN, Bhuyan UN. Renal tubular acidosis preceding systemic lupus erythematosus. Pediatr Nephrol 1993; 7:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/16\">",
"      Batlle D, Ghanekar H, Jain S, Mitra A. Hereditary distal renal tubular acidosis: new understandings. Annu Rev Med 2001; 52:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/17\">",
"      Rodr&iacute;guez-Soriano J. New insights into the pathogenesis of renal tubular acidosis--from functional to molecular studies. Pediatr Nephrol 2000; 14:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/18\">",
"      Nash MA, Torrado AD, Greifer I, et al. Renal tubular acidosis in infants and children. Clinical course, response to treatment, and prognosis. J Pediatr 1972; 80:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/19\">",
"      Rodriguez Soriano J, Boichis H, Stark H, Edelmann CM Jr. Proximal renal tubular acidosis. A defect in bicarbonate reabsorption with normal urinary acidification. Pediatr Res 1967; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/20\">",
"      Donckerwolcke RA, van Stekelenburg GJ, Tiddens HA. A case of bicarbonate-losing renal tubular acidosis with defective carboanhydrase activity. Arch Dis Child 1970; 45:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/21\">",
"      Igarashi T, Inatomi J, Sekine T, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet 1999; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/22\">",
"      Jentsch TJ, Keller SK, Koch M, Wiederholt M. Evidence for coupled transport of bicarbonate and sodium in cultured bovine corneal endothelial cells. J Membr Biol 1984; 81:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/23\">",
"      Igarashi T, Inatomi J, Sekine T, et al. Novel nonsense mutation in the Na+/HCO3- cotransporter gene (SLC4A4) in a patient with permanent isolated proximal renal tubular acidosis and bilateral glaucoma. J Am Soc Nephrol 2001; 12:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/24\">",
"      Winsnes A, Monn E, Stokke O, Feyling T. Congenital persistent proximal type renal tubular acidosis in two brothers. Acta Paediatr Scand 1979; 68:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/25\">",
"      Igarashi T, Ishii T, Watanabe K, et al. Persistent isolated proximal renal tubular acidosis--a systemic disease with a distinct clinical entity. Pediatr Nephrol 1994; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/26\">",
"      Brenes LG, Brenes JN, Hernandez MM. Familial proximal renal tubular acidosis. A distinct clinical entity. Am J Med 1977; 63:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/27\">",
"      Katzir Z, Dinour D, Reznik-Wolf H, et al. Familial pure proximal renal tubular acidosis--a clinical and genetic study. Nephrol Dial Transplant 2008; 23:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/28\">",
"      Wang T, Yang CL, Abbiati T, et al. Mechanism of proximal tubule bicarbonate absorption in NHE3 null mice. Am J Physiol 1999; 277:F298.",
"     </a>",
"    </li>",
"    <li>",
"     Foreman, JW. Fanconi syndrome and cystinosis. In: Pediatric Nephrology, 3rd ed, Holliday, MA, Barratt, TM, Avner, ED (Eds), Williams &amp; Wilkins, Philadelphia 1994. p.537.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/30\">",
"      Tashian RE. Genetics of the mammalian carbonic anhydrases. Adv Genet 1992; 30:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/31\">",
"      Sly WS, Hewett-Emmett D, Whyte MP, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 1983; 80:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/32\">",
"      Whyte MP, Murphy WA, Fallon MD, et al. Osteopetrosis, renal tubular acidosis and basal ganglia calcification in three sisters. Am J Med 1980; 69:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/33\">",
"      Roth DE, Venta PJ, Tashian RE, Sly WS. Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci U S A 1992; 89:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/34\">",
"      Pereira PC, Miranda DM, Oliveira EA, Silva AC. Molecular pathophysiology of renal tubular acidosis. Curr Genomics 2009; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17768/abstract/35\">",
"      Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6121 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17768=[""].join("\n");
var outline_f17_22_17768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISTAL (TYPE 1) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acquired causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Recessive form",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dominant form",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROXIMAL (TYPE 2) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Isolated proximal RTA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fanconi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical findings of Fanconi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MIXED (TYPE 3) RTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HYPOALDOSTERONISM (TYPE 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/42/23211\" title=\"table 1\">",
"      Characteristics of RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/48/18188\" title=\"table 2\">",
"      Major causes of type 1 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/21/24924\" title=\"table 3\">",
"      Inherited causes RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22604\" title=\"table 4\">",
"      Major causes of type 2 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/0/41995\" title=\"table 5\">",
"      Major causes of hypoaldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24760?source=related_link\">",
"      Epidemiology and toxicity of cadmium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=related_link\">",
"      Ifosfamide nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17769="Overview of topical hemostatic agents used in the operating room";
var content_f17_22_17769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of topical hemostatic agents used in the operating room",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Elizabeth Peralta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17769/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/22/17769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H336519931\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical hemostatic agents are used when surgical hemostasis is inadequate or impractical. The majority of routine, elective operations are performed in patients with normal hemostasis and with minimal blood loss",
"   </p>",
"   <p>",
"    The mechanism of action, indications, and the clinical application of the most common topical hemostatic agents used in surgery are reviewed here. Devices used to achieve surgical hemostasis through vascular control during dissection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164152142\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative bleeding is controlled using standard surgical techniques and electrocautery with the adjunctive use of topical hemostatic agents.",
"   </p>",
"   <p>",
"    Electrocautery may not be useful for controlling bleeding in some surgical fields such as around nerves, medullary bone surfaces, needle-hole bleeding from vascular grafts, and raw areas on cut surfaces. Patients who are anticoagulated and those with bleeding diatheses (eg, factor deficiencies, disseminated intravascular coagulation), or have platelet dysfunction (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy) can continue to ooze from surgical surfaces in spite of adequate surgical hemostasis.",
"   </p>",
"   <p>",
"    Under ideal circumstances, patients with hemostatic abnormalities have their underlying defects corrected prior to proceeding with surgery; however, this is not always possible. Anticoagulated patients, patients receiving antiplatelet therapy, and those with congenital or acquired bleeding diatheses may require emergency surgical procedures to manage trauma or unrelated conditions or to manage hemorrhage that is a result of their disorder. Under these circumstances, correction of the hemostatic defect is undertaken en route to or simultaneously with the procedure. Hemostatic abnormalities can also develop during the course of surgery (eg, hypothermia, disseminated intravascular coagulation).",
"   </p>",
"   <p>",
"    Topical hemostatic agents are primarily used for diffuse bleeding from:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peritoneal or pleural surfaces",
"     </li>",
"     <li>",
"      Cut surfaces of solid organs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cut edges of bone",
"     </li>",
"     <li>",
"      Bleeding near nerves",
"     </li>",
"     <li>",
"      Bleeding near vital structures at risk for cautery-induced injury",
"     </li>",
"     <li>",
"      Bleeding from vascular structures or grafts due to suture holes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nasal structures as nasal packing [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dental extraction sites [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical hemostatic agents are also used for other purposes including the management of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Air leak following lung resection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Eardrum perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endoscopic control of gastrointestinal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801744950\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical hemostatic agents should not be used intravascularly because they will cause thrombosis, or in confined spaces where expansion of the product could lead to compression. (See",
"    <a class=\"local\" href=\"#H336520087\">",
"     'Adverse effects and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801744936\">",
"    <span class=\"h1\">",
"     AVAILABLE PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main categories of topical hemostatic agents are physical agents, which promote hemostasis using a passive substrate, and biologically active agents, which enhance coagulation at the bleeding site (",
"    <a class=\"graphic graphic_table graphicRef71852 \" href=\"UTD.htm?19/54/20334\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637221\">",
"    <span class=\"h2\">",
"     Physical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical agents promote hemostasis through several effects. The matrix material provides a stimulus that activates platelets and the extrinsic pathway and provides a scaffold for thrombus deposition. The dry matrix also absorbs water and concentrates hemostatic factors at the site of bleeding, and tamponades bleeding vessels by exerting pressure. The various physical agents include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637255\">",
"    <span class=\"h3\">",
"     Bone wax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood oozing from the cut surface of medullary bone is a common feature of median sternotomy, orthopedic, and neurosurgery procedures. Bone wax, which is composed of beeswax, paraffin, and wax-softening agents, physically occludes bleeding vessels within bone to stop bleeding. When using bone wax, a minimal amount should be used and it is rubbed across the surface of the bone surface without leaving a raised plug.",
"   </p>",
"   <p>",
"    Bone wax is inexpensive and effective, but can lead to infection or granuloma formation which can interfere with bone healing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one retrospective study in neurosurgical patients, the incidence of surgical-site infection significantly decreased when bone wax was no longer used (14.2 versus 1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637262\">",
"    <span class=\"h3\">",
"     Ostene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ostene, an effective alternative to bone wax, is a wax-like compound of a water-soluble alkaline oxide copolymer that occludes bleeding vessels in bone, similar to bone wax, but it does not persist in the wound as a foreign body. In animal studies comparing Ostene with bone wax, Ostene did not remain in the wound beyond three weeks and bone healing was more pronounced in the Ostene group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637269\">",
"    <span class=\"h3\">",
"     Dry matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry agents form a matrix that activates the coagulation cascade and serves as a scaffold onto which thrombus can easily form. These agents are easy to use; however, they are less effective if bleeding is brisk.",
"   </p>",
"   <p>",
"    The agent is applied to the site of bleeding followed by gentle pressure with a surgical sponge. Care must be taken in removing the sponge because these agents generally adhere to the underlying tissue and will remove the clot that has formed if removed too quickly. A useful technique for removal is wetting the sponge thoroughly and lifting the sponge from one edge slowly rolling the sponge off the clotted area. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801744470\">",
"    <span class=\"h4\">",
"     Oxidized regenerated cellulose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     Oxidized regenerated cellulose",
"    </a>",
"    (ORC) is a dry, absorbable sterile mesh (eg, Surgicel) that can be applied directly to an area of bleeding. A single-layer sheet is fully absorbed in about 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/16\">",
"     16",
"    </a>",
"    ]. Results are optimal if bleeding is minimal (ie, oozing).",
"   </p>",
"   <p>",
"    ORC is commonly used to control bleeding at vascular anastomotic sites, the cut surfaces of solid organs, and retroperitoneal or pelvic surfaces after lymphadenectomy. Because ORC is pliable, it can be rolled and passed easily through laparoscopic trocars [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In vitro studies have found that ORC has bactericidal activity against a wide range of gram-positive and negative organisms because of its acidic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The low pH also inhibits proteases and elastase, which may be beneficial in chronic wounds; however, this same property may inhibit its resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/21\">",
"     21",
"    </a>",
"    ]. Residual ORC is associated with infection and adhesion formation. In one study of 360 patients with postoperative pelvic abscess, unabsorbed ORC was identified as a risk factor, and in some cases un-resorbed ORC was found at laparotomy more than 12 months after it was placed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801744477\">",
"    <span class=\"h4\">",
"     Gelatin matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gelatin (eg, Gelfoam, Surgifoam) is a hydrocolloid made from acid partial hydrolysis of porcine-derived collagen that is whipped into foam and then dried. It is available in sponge or powder form [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Gelatin sponge absorbs blood or fluid up to 40 times its weight and it expands up to 200 percent in its dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dry sponge form can be tailored to any shape and although rigid when dry, the sponge is pliable after moistening and passes easily through laparoscopic ports. Once in place, pressure is applied for several minutes to achieve hemostasis. The sponge can be left in place and is completely absorbed after four to six weeks.",
"    <br/>",
"    <br/>",
"    Because gelatin foam has a neutral pH, it does not activate thrombin, and thus, it is common practice to moisten it with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    to synergize the effects of these agents. The relative effectiveness of gelatin foam with or without thrombin has not been the subject of clinical trials. In a pig model of splenic laceration, gelatin foam without thrombin required two 20-second periods of finger pressure to stop breakthrough bleeding, while gelatin foam with thrombin needed only one 20-second period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The disadvantages of gelatin include an increased incidence of infection, granuloma, and fibrosis formation, and, similar to dry matrix product, the potential for disruption of the clot if the sponge is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Although all brands of gelatin matrix are derived from porcine connective tissue, it is not considered to be antigenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637276\">",
"    <span class=\"h4\">",
"     Microporous polysaccharide spheres",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microporous polysaccharide spheres (MPS) (eg, Arista) are derived from potato starch, which accelerates clot formation by acting as a molecular sieve to absorb water and concentrate platelets and blood proteins. MPS is available in powder form.",
"   </p>",
"   <p>",
"    Microporous polysaccharide spheres are used by first applying pressure to the bleeding site with a dry surgical sponge for two minutes to achieve a relatively dry surface, then liberally applying the powder with the bellows applicator. Gentle pressure is reapplied with a fresh surgical sponge for one to two minutes until hemostasis is achieved.",
"   </p>",
"   <p>",
"    The advantages of MPS include low cost, rapid absorption within 48 hours, and freedom from transmissible viruses or alloantigens. In addition, MPS does not act as a nidus for infection or cause foreign body reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/27\">",
"     27",
"    </a>",
"    ]. It can also be used with blood salvage circuits in conjunction with cell washing and the use of a 40 micron transfusion filter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637298\">",
"    <span class=\"h4\">",
"     Microfibrillar collagen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microfibrillar collagen (MC) is an absorbable acid salt obtained from bovine collagen (eg, Avitene). MC acts as a scaffold for clot formation and activates platelets. It is indicated for use in neurosurgery and urology.",
"   </p>",
"   <p>",
"    MC can be applied directly to the bleeding site as a powder [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], but foam sheet formulations (Avitene Ultrafoam) are available. MC is fully absorbed within three months.",
"   </p>",
"   <p>",
"    MC remains effective with heparinization, but is less effective when platelet counts are below",
"    <span class=\"nowrap\">",
"     20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    MC is contraindicated in blood scavenging systems because the fibers can pass through the filters causing embolization, and potentially disseminated intravascular coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H801744850\">",
"    <span class=\"h3\">",
"     External agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outside the operating room, in rescue or battlefield situations, external hemorrhage is generally controlled with direct pressure and standard dressings; however, when these are ineffective, external topical agents can be used as specialized dressings to temporize hemorrhage until definitive management is possible. Available products include zeolite granules (eg, QuikClot), and chitosan (eg, HemCon, Chitoflex). These products are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H10#H10\">",
"     \"Fibrin sealant\", section on 'Other hemostatic preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the operating room, these agents should be removed under anesthesia, prior to prepping and draping unless there is a risk of severe, life-threatening hemorrhage upon removal of the dressing. In this situation, proximal vascular control is obtained prior to removing the material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637305\">",
"    <span class=\"h2\">",
"     Biologically active agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologically active agents augment hemostasis. Hemostasis is a dynamic process occurring in four general phases (initiation and formation of the platelet plug, propagation of the clotting through the coagulation cascade, termination of clotting by antithrombotic control mechanisms, and removal of the clot by fibrinolysis). These are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637521\">",
"    <span class=\"h3\">",
"     Topical thrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     Topical thrombin",
"    </a>",
"    is reconstituted from a lyophilized powder. It can be applied using a sprayer, which is useful for managing diffuse bleeding from oozing peritoneal and pleural surfaces, or applied with a needle and syringe to direct its application to a specific area of bleeding. Topical thrombin can also be used in conjunction with a gelatin matrix agent (sponge or granules) that provides the thrombin with an immediate scaffold for clot formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H801744477\">",
"     'Gelatin matrix'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     Topical thrombin",
"    </a>",
"    in combination with gelatin foam or granules is useful for promoting hemostasis at vascular graft suture hole sites. Due to its liquid nature, thrombin applied in combination with gelatin granules (eg, FloSeal, Surgiflo) may control bleeding more quickly than thrombin-soaked pieces of gelatin foam. (See",
"    <a class=\"local\" href=\"#H365552602\">",
"     'Effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Urine does not significantly inhibit thrombin or thrombin-fibrin combination products. The urologic literature favors thrombin-based agents over dry matrix agents (and suture material), which can act as a nidus for stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/33\">",
"     33",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <br/>",
"    Human thrombin and a recombinant thrombin are available for use, largely replacing bovine thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrin sealant\", section on 'Source of thrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637319\">",
"    <span class=\"h3\">",
"     Fibrin sealant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrin sealants (eg, Tisseel, Vitagel, Cryoseal, Evicel) are a two-component system that includes a solution of concentrated fibrinogen and factor XII, and a solution of thrombin and calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. When mixed together just prior to use, a fibrin clot forms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/16\">",
"     16",
"    </a>",
"    ]. In some preparations, an antifibrinolytic agent is included to prevent lysis of the clot [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A history of prior anaphylactic reactions to plasma products or of IgA deficiency contraindicates the use of fibrin sealants prepared from plasma or cryoprecipitate. Commercial preparations are available but autologous preparations can also be made, virtually eliminating any infectious disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The formulation and preparation of fibrin sealants is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    Prior to use, the frozen product must be thawed completely, which takes about 15 minutes. The two components are applied simultaneously using a two-syringe technique. Commercially available preparations consist of a combination plunger, side-by-side syringes and a dual needle-tip to facilitate even application of each component.",
"   </p>",
"   <p>",
"    Fibrin sealant can be used to control bleeding at vascular anastomotic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. As an example of their efficacy, one study randomly assigned 140 patients to fibrin sealant (Tisseel) or manual pressure following the creation of an arterial-graft (polytetrafluoroethylene) anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/40\">",
"     40",
"    </a>",
"    ]. A significantly higher percentage of graft anastomoses were controlled at four minutes in the fibrin sealant group compared with the manual compression group (63 versus 31 percent), and with less need to employ an alternative hemostatic treatment (19 versus 40 percent).",
"   </p>",
"   <p>",
"    <br/>",
"    Fibrin",
"    <span class=\"nowrap\">",
"     sealants/glue",
"    </span>",
"    preparations can also be used in laparoscopy but require a long dual-lumen applicator [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/28,29,43\">",
"     28,29,43",
"    </a>",
"    ]. The application is frequently complicated by obstruction of the applicator tip. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=see_link\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709637333\">",
"    <span class=\"h2\">",
"     Tissue adhesives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents with adhesive qualities are most commonly used to close skin wounds, but other applications in surgery have been investigated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyanoacrylate &ndash; Cyanoacrylate tissue adhesives octyl-2-cyanoacrylate (eg, Dermabond) and butyl-2-cyanoacrylate (eg, Histoacryl)] are liquid monomers that change to strong polymers with exposure to moisture. Cyanoacrylate is used primarily for skin incision closure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/44\">",
"       44",
"      </a>",
"      ]. The use of cyanoacrylate for closure of minor wounds is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=see_link\">",
"       \"Superficial wound repair with tissue adhesives\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Cyanoacrylate has also been used endoscopically to seal bleeding esophageal varices or peptic ulcer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/9-11\">",
"       9-11",
"      </a>",
"      ], repair of the cornea, [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/45,46\">",
"       45,46",
"      </a>",
"      ], to fixate skin grafts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/47\">",
"       47",
"      </a>",
"      ], repair vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/48,49\">",
"       48,49",
"      </a>",
"      ], fixate mesh during hernia surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/50\">",
"       50",
"      </a>",
"      ], during circumcision [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/51-56\">",
"       51-56",
"      </a>",
"      ], and to seal dural leaks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/57\">",
"       57",
"      </a>",
"      ], air leaks (ie, bronchopleural fistula), and lymphatic leaks.",
"     </li>",
"     <li>",
"      Albumin based &ndash; Albumin based tissue adhesives combine albumin and an organic compound immediately prior to use. The mixture forms a matrix with adhesive properties. One such compound consists of a combination of bovine albumin and glutaraldehyde (Bioglue) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/58-64\">",
"       58-64",
"      </a>",
"      ]. Another example is the combination of human albumin and polyethylene glycol (FocalSeal-L, Progel), which has been used to treat pulmonary air leak [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polyethylene glycol hydrogel &ndash; A completely synthetic tissue adhesive (CoSeal) combines two forms of polyethylene glycol (PEG) to form a hydrogel. This compound has been used to treat bleeding vascular graft suture holes. In a multicenter trial that randomly assigned 148 patients undergoing polytetrafluoroethylene (PTFE) vascular graft placement to PEG hydrogel or",
"      <span class=\"nowrap\">",
"       thrombin/gelatin",
"      </span>",
"      sponge, the median time to achieve vascular control was significantly less for those treated with PEG hydrogel (16.5 versus 189 seconds) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/67\">",
"       67",
"      </a>",
"      ]. However, no differences were seen at the primary endpoint of 10 minutes (86 versus 84 percent). A drawback of PEG hydrogel is its tendency to swell up to four times its initial volume over a 24-hour period, with some continued swelling thereafter, thus limiting its application in confined spaces.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336520087\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of topical hemostatic agents are related to the composition and characteristics of the preparation, location of placement, and absorption time. Excessive amounts of a slowly degrading product can serve as a nidus for infection and agents placed into a confined place can cause compression of surrounding structures, particularly if the product has a tendency to expand. As examples, gelatin foam matrix in combination with thrombin has complicated eye and spine surgery causing blindness and paralysis, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151365\">",
"    <span class=\"h2\">",
"     Impaired wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess application of topical hemostatic agents can impede wound healing. Granuloma formation has been reported with the use of microfibrillar collagen, gelatin foam, and cyanoacrylate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/16,68,69\">",
"     16,68,69",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In addition",
"    <strong>",
"     ,",
"    </strong>",
"    the metabolites of cyanoacrylates (ie, cyanoacetate and formaldehyde) can cause an inflammatory response in the surrounding tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151386\">",
"    <span class=\"h2\">",
"     Surgical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many clinical reports of wound infections associated with the use of hemostatic agents. Adverse factors such as emergency procedure, transfusion, and prolonged operative time are associated with an increased risk of surgical wound infection and frequently coexist with the need for hemostatic agents, and thus, any analysis of the risk of infection due to hemostatic agent is confounded. The risk of infection may be minimized by removing excess topical hemostatic agents from the wound after hemostasis is achieved, when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151379\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions (including anaphylaxis) are associated primarily with bovine-derived fibrin sealants. These products should not be used in patients with a history of prior anaphylactic reactions to plasma products or IgA deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H15#H15\">",
"     \"Fibrin sealant\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    A single case report of a systemic allergic reaction during a laparoscopic cholecystectomy was associated with the use of microfibrillar collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151399\">",
"    <span class=\"h2\">",
"     Blood-borne disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential transmission of infectious disease (eg, HIV, hepatitis), even from screened and tested blood, is a risk of any product that contains blood components. The use of recombinant human thrombin should reduce the risk. Health care workers in the operating room should exercise extra caution when using thrombin-derived products, particularly if used in an aerosolized form. The risk of transmission of blood-borne illness due to fibrin sealants is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link&amp;anchor=H15#H15\">",
"     \"Fibrin sealant\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151406\">",
"    <span class=\"h2\">",
"     Vascular thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No increased rate of vascular or graft thrombosis has been reported with the topical use of hemostatic agents. Although there were concerns in the past that polyester grafts (eg, Dacron) could allow thrombin to leak into the lumen and lead to thrombosis and embolism, this is not an issue with currently available grafts. Topical hemostatic agents should",
"    <strong>",
"     not",
"    </strong>",
"    be injected into a blood vessel or within an opened vessel.",
"   </p>",
"   <p>",
"    Embolization of gelatin matrix into the bloodstream from spraying it onto the cut surface of bone has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood salvage (eg, CellSaver) should",
"    <strong>",
"     not",
"    </strong>",
"    be used when blood has been in contact with gelatin or collagen, because fibers can pass through the filters and cause intravascular coagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365552602\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-quality data establishing the effectiveness of topical hemostatic agents in surgery are lacking. The package insert and United States Food and Drug Administration (FDA) medical device application for each hemostatic agent contain data from animal studies and unpublished trials that compare its effectiveness usually with gelatin foam or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"     oxidized regenerated cellulose",
"    </a>",
"    . Published randomized trials in which topical agents were used for minor intraoperative bleeding sites include the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In three trials involving patients undergoing vascular, spinal, or cardiac surgery, hemostatic sealants (Floseal, Proceed) were found to have significantly higher rates of hemostasis (88 to 99 versus 57 to 93 percent) at 10 minutes after application compared with thrombin-gelatin combination [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/24,73,74\">",
"       24,73,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 69 patients undergoing obstetric, gynecologic, general, vascular, and cardiothoracic surgery, an autologous fibrin sealant resulted in a significantly higher rate of hemostasis (94 versus 65 percent) at five minutes after application compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"       oxidized regenerated cellulose",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter trial, 333 patients were randomly assigned to receive the fibrin sealant or a conventional topical hemostatic agent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/76\">",
"       76",
"      </a>",
"      ]. Fibrin sealant controlled bleeding successfully within five minutes of application in significantly more patients (93 versus 12 percent) compared with conventional topical agents. There were no differences in volume of blood products used or mortality between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336520109\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of topical hemostatic agents to use depends upon amount and location of bleeding, the availability of a given agent, cost considerations, and surgeon preference [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biologically active agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"     topical thrombin",
"    </a>",
"    , fibrin seal) are more useful for brisk bleeding compared with dry matrix agents (eg, gelatin matrix) and are more effective in the setting of coagulopathy or in defibrinated fluid such as pooled serum or cerebrospinal fluid.",
"   </p>",
"   <p>",
"    Although more expensive, fibrin sealants have significantly higher rates of hemostatic control compared with thrombin-gelatin combinations. Fibrin sealant and bovine albumin-glutaraldehyde tissue adhesive (eg, Bioglue) are appropriate choices when moderate bleeding does not respond to other measures. (See",
"    <a class=\"local\" href=\"#H365552602\">",
"     'Effectiveness'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164151169\">",
"    <span class=\"h2\">",
"     Surgical scenarios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for using topical hemostatic agents for various surgical scenarios are given below, including a cost for each agent. Cost key: &cent;=less than 50 dollars, $= 50 to 100 dollars, $$=101 to 300 dollars, $$$=301 to 500 dollars, $$$$ 501 to 750 dollars.",
"   </p>",
"   <p>",
"    Large artery",
"    <span class=\"nowrap\">",
"     bleeding/repair",
"    </span>",
"    (aorta, femoral, carotid):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bioglue ($$$$) is approved in the United States for large vessel repair in cardiovascular surgery.",
"     </li>",
"     <li>",
"      Other topical hemostats are not generally approved for arterial bleeding, except microporous polysaccharide spheres (Arista) ($), which has been evaluated in a femoral artery porcine model (to a systolic blood pressure of 155 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulsatile needle hole bleeding in vessel adventitia or in vascular graft material:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply microporous polysaccharide spheres (Arista) ($).",
"     </li>",
"     <li>",
"      Apply thrombin-soaked gelatin foam (Gelfoam, Surgifoam) ($) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"       oxidized regenerated cellulose",
"      </a>",
"      (eg, Surgicel) ($).",
"     </li>",
"     <li>",
"      Apply gelatin matrix-thrombin combination (eg, FloSeal, Surgiflo) ($$).",
"     </li>",
"     <li>",
"      Spray fibrin sealant (eg, Tisseel, Evicel, Hemaseel APR, Crosseal) ($$$$).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulsatile external exsanguinating hemorrhage, preoperative setting (arterial rupture, arterial injury):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply compression with zeolite bandage (eg, QuikClot) ($), or chitosan bandage (eg, HemCon, Chitoflex) ($$).",
"     </li>",
"     <li>",
"      Pack with dry fibrin sealant dressing ($$$$+).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spleen, liver, kidney parenchymal surface post-trauma or partial resection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wrap with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"       oxidized regenerated cellulose",
"      </a>",
"      (eg, Surgicel) ($) or microfibrillar collagen (Avitene Ultrawrap) ($$$) with or without suture fixation.",
"     </li>",
"     <li>",
"      Apply microporous polysaccharide spheres (eg, Arista) and hold sponge pressure for several minutes ($).",
"     </li>",
"     <li>",
"      Spray with thrombin ($).",
"     </li>",
"     <li>",
"      Apply gelatin matrix-thrombin combination (eg, FloSeal, Surgiflo) ($$).",
"     </li>",
"     <li>",
"      Spray fibrin sealant (eg, Tisseel, Evicel, Hemaseel APR, Crosseal) ($$$$).",
"     </li>",
"     <li>",
"      Apply fibrin glue-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"       oxidized regenerated cellulose",
"      </a>",
"      &ldquo;sandwich&rdquo;. This technique has been described for sutureless hemostasis of laparoscopic wedge excisions of the kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Venous or capillary oozing from area of dissection or de-serosalization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/54/36706?source=see_link\">",
"       oxidized regenerated cellulose",
"      </a>",
"      (eg, Surgicel Nu-Knit, Surgicel Fibrillar) with sponges and hand pressure ($ to $$).",
"     </li>",
"     <li>",
"      Apply microporous polysaccharide spheres (eg, Arista) and hold sponge pressure for several minutes ($ to $$).",
"     </li>",
"     <li>",
"      Spray with thrombin ($ to $$).",
"     </li>",
"     <li>",
"      Spray with fibrin sealant (eg, Tisseel, Evicel, Hemaseel APR, Crosseal) ($$$$).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cavity or potential space, nerve or other tissue not amenable to cautery, need to avoid compression of nerve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply microporous polysaccharide spheres (eg, Arista) and hold sponge pressure for several minutes. Irrigate away remaining powder ($).",
"     </li>",
"     <li>",
"      Avitene Flour, EndoAvitene (OK to leave in place) ($$).",
"     </li>",
"     <li>",
"      Spray with fibrin sealant (eg, Tisseel, Evicel, Hemaseel APR, Crosseal) ($$$$).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365552979\">",
"    <span class=\"h2\">",
"     Cost considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical hemostatic agents are generally prepackaged for one-time use in quantities that are generally sufficient to manage bleeding from a single site. Although these preparations should not be used unnecessarily, they are cost-effective if they save operative time, reduce transfusions, and prevent a return to the operating room. The cost of these agents falls in the range between an electrosurgery pen and the handset of various tissue-sealing energy sources (eg, ultrasonic dessicator).",
"   </p>",
"   <p>",
"    Less expensive agents are frequently used in a routine or preventive setting to minimize blood loss. The more expensive agents (fibrin sealants and microfibrillar collagen) are often more effective in the setting of coagulopathy or anticoagulation and are frequently the preferred choice when bleeding is not easily controlled. (See",
"    <a class=\"local\" href=\"#H365552602\">",
"     'Effectiveness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although it is easy to compare the direct cost of the various topical hemostatic agents, it is difficult to assess the associated costs of surgery related to hemostatic agents such as operating room time and blood transfusion products. Using length of stay (LOS) as a rough estimate of cost, a study of 36,950 patients correlated length of stay after cardiothoracic surgery with the choice of hemostatic agent and found significantly less likelihood of exceeding expected LOS for fibrin sealant (FloSeal) compared with other hemostatic agents (Surgicel + thrombin, Gelfoam + thrombin) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17769/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336520116\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A major goal during any surgery is minimization of blood loss, which reduces the need for blood transfusion. Significant bleeding during surgery is controlled with vessel ligation, suturing, and electrocautery. Topical hemostatic agents are useful adjuncts to surgical hemostasis for controlling nonspecific bleeding. (See",
"      <a class=\"local\" href=\"#H336519931\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical hemostatic agents work primarily by exerting physical effects or by enhancing existing hemostatic mechanisms (",
"      <a class=\"graphic graphic_table graphicRef71852 \" href=\"UTD.htm?19/54/20334\">",
"       table 1",
"      </a>",
"      ). Physical agents include bone waxes, dry matrix agents, and external agents. Agents that enhance normal hemostatic mechanisms include thrombin-based products and tissue adhesives. (See",
"      <a class=\"local\" href=\"#H801744936\">",
"       'Available products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects and complications from topical hemostatic agents are generally uncommon. Most problems can be avoided by limiting the amount of agent remaining within the wound once hemostasis has been achieved. Complications related to thrombin-based agents, which are blood products, include the potential for transmission of blood-borne disease and anaphylaxis with the bovine-derived agents. Other problems that can arise include impaired wound and infection. (See",
"      <a class=\"local\" href=\"#H336520087\">",
"       'Adverse effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of which topical hemostatic agent to use depends upon the character, amount, and location of bleeding; the availability of a given agent; surgeon preference; and cost considerations. Dry matrix agents are less useful when bleeding is brisk. Fibrin sealant and bovine albumin-glutaraldehyde tissue adhesive (eg, Bioglue) are appropriate choices when moderate bleeding does not respond to other measures. (See",
"      <a class=\"local\" href=\"#H336520109\">",
"       'Choice of agent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H365552602\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/1\">",
"      Berrevoet F, de Hemptinne B. Use of topical hemostatic agents during liver resection. Dig Surg 2007; 24:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/2\">",
"      Ochsner MG, Maniscalco-Theberge ME, Champion HR. Fibrin glue as a hemostatic agent in hepatic and splenic trauma. J Trauma 1990; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/3\">",
"      Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery 2011; 149:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/4\">",
"      Matthew TL, Spotnitz WD, Kron IL, et al. Four years' experience with fibrin sealant in thoracic and cardiovascular surgery. Ann Thorac Surg 1990; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/5\">",
"      Vaiman M, Eviatar E, Segal S. Effectiveness of second-generation fibrin glue in endonasal operations. Otolaryngol Head Neck Surg 2002; 126:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/6\">",
"      Rakocz M, Mazar A, Varon D, et al. Dental extractions in patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol 1993; 75:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/7\">",
"      Malapert G, Hanna HA, Pages PB, Bernard A. Surgical sealant for the prevention of prolonged air leak after lung resection: meta-analysis. Ann Thorac Surg 2010; 90:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/8\">",
"      Niklasson A, Tano K. The Gelfoam&reg; plug: an alternative treatment for small eardrum perforations. Laryngoscope 2011; 121:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/9\">",
"      Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut 2010; 59:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/10\">",
"      Chang YJ, Park JJ, Joo MK, et al. Long-term outcomes of prophylactic endoscopic histoacryl injection for gastric varices with a high risk of bleeding. Dig Dis Sci 2010; 55:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/11\">",
"      Cheng CL, Liu NJ, Lee CS, et al. Endoscopic management of Dieulafoy lesions in acute nonvariceal upper gastrointestinal bleeding. Dig Dis Sci 2004; 49:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/12\">",
"      Sudmann B, Bang G, Sudmann E. Histologically verified bone wax (beeswax) granuloma after median sternotomy in 17 of 18 autopsy cases. Pathology 2006; 38:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/13\">",
"      Gibbs L, Kakis A, Weinstein P, Conte JE Jr. Bone wax as a risk factor for surgical-site infection following neurospinal surgery. Infect Control Hosp Epidemiol 2004; 25:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/14\">",
"      Magyar CE, Aghaloo TL, Atti E, Tetradis S. Ostene, a new alkylene oxide copolymer bone hemostatic material, does not inhibit bone healing. Neurosurgery 2008; 63:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/15\">",
"      Vestergaard RF, Jensen H, Vind-Kezunovic S, et al. Bone healing after median sternotomy: a comparison of two hemostatic devices. J Cardiothorac Surg 2010; 5:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/16\">",
"      Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/17\">",
"      Sharma JB, Malhotra M. Topical oxidized cellulose for tubal hemorrhage hemostasis during laparoscopic sterilization. Int J Gynaecol Obstet 2003; 82:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/18\">",
"      Sharma JB, Malhotra M, Pundir P. Laparoscopic oxidized cellulose (Surgicel) application for small uterine perforations. Int J Gynaecol Obstet 2003; 83:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/19\">",
"      Spangler D, Rothenburger S, Nguyen K, et al. In vitro antimicrobial activity of oxidized regenerated cellulose against antibiotic-resistant microorganisms. Surg Infect (Larchmt) 2003; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/20\">",
"      Wiseman DM, Kamp LF, Saferstein L, et al. Improving the efficacy of INTERCEED Barrier in the presence of blood using thrombin, heparin or a blood insensitive barrier, modified INTERCEED (nTC7). Prog Clin Biol Res 1993; 381:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/21\">",
"      Smeets R, Ulrich D, Unglaub F, et al. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J 2008; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/22\">",
"      Fagotti A, Costantini B, Fanfani F, et al. Risk of postoperative pelvic abscess in major gynecologic oncology surgery: one-year single-institution experience. Ann Surg Oncol 2010; 17:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/23\">",
"      Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol 2006; 176:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/24\">",
"      Weaver FA, Hood DB, Zatina M, et al. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg 2002; 16:286.",
"     </a>",
"    </li>",
"    <li>",
"     file://labeling.pfizer.com/ShowLabeling.aspx?id=573 (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     Connolly R. A Comparison of Avitene Ultrafoam  versus gelfoam with and thout thrombin to effectively control bleeding. In: Patent US, ed. freepatentsonline. USA: C.R.Bard, Inc;  2002:14-15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/27\">",
"      Ereth MH, Schaff M, Ericson EF, et al. Comparative safety and efficacy of topical hemostatic agents in a rat neurosurgical model. Neurosurgery 2008; 63:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/28\">",
"      Borten M, Friedman EA. Translaparoscopic hemostasis with microfibrillar collagen in lieu of laparotomy. A report of two cases. J Reprod Med 1983; 28:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/29\">",
"      Holub Z, Jabor A. Laparoscopic management of bleeding after laparoscopic or vaginal hysterectomy. JSLS 2004; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/30\">",
"      Schoenecker JG, Johnson RK, Fields RC, et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003; 197:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/31\">",
"      Raga F, Sanz-Cortes M, Bonilla F, et al. Reducing blood loss at myomectomy with use of a gelatin-thrombin matrix hemostatic sealant. Fertil Steril 2009; 92:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/32\">",
"      Han LY, Schimp V, Oh JC, Ramirez PT. A gelatin matrix-thrombin tissue sealant (FloSeal) application in the management of groin breakdown after inguinal lymphadenectomy for vulvar cancer. Int J Gynecol Cancer 2004; 14:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/33\">",
"      Uribe CA, Eichel L, Khonsari S, et al. What happens to hemostatic agents in contact with urine? An in vitro study. J Endourol 2005; 19:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/34\">",
"      Kram HB, Nathan RC, Mackabee JR, et al. Clinical use of nonautologous fibrin glue. Am Surg 1988; 54:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/35\">",
"      Harris DM, Siedentop KH, Ham KR, Sanchez B. Autologous fibrin tissue adhesive biodegration and systemic effects. Laryngoscope 1987; 97:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/36\">",
"      Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion 2008; 48:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/37\">",
"      Reiss RF, Oz MC. Autologous fibrin glue: production and clinical use. Transfus Med Rev 1996; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/38\">",
"      Oz MC, Jeevanandam V, Smith CR, et al. Autologous fibrin glue from intraoperatively collected platelet-rich plasma. Ann Thorac Surg 1992; 53:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/39\">",
"      Quigley RL, Perkins JA, Gottner RJ, et al. Intraoperative procurement of autologous fibrin glue. Ann Thorac Surg 1993; 56:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/40\">",
"      Saha SP, Muluk S, Schenk W 3rd, et al. A prospective randomized study comparing fibrin sealant to manual compression for the treatment of anastomotic suture-hole bleeding in expanded polytetrafluoroethylene grafts. J Vasc Surg 2012; 56:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/41\">",
"      Chalmers RT, Darling Iii RC, Wingard JT, et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg 2010; 97:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/42\">",
"      Saha SP, Muluk S, Schenk W 3rd, et al. Use of fibrin sealant as a hemostatic agent in expanded polytetrafluoroethylene graft placement surgery. Ann Vasc Surg 2011; 25:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/43\">",
"      Kitamura K, Yasuoka R, Ohara M, et al. How safe are the xenogeneic hemostats?--Report of a case of severe systemic allergic reaction. Surg Today 1995; 25:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/44\">",
"      Coulthard P, Worthington H, Esposito M, et al. Tissue adhesives for closure of surgical incisions. Cochrane Database Syst Rev 2004; :CD004287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/45\">",
"      Vote BJ, Elder MJ. Cyanoacrylate glue for corneal perforations: a description of a surgical technique and a review of the literature. Clin Experiment Ophthalmol 2000; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/46\">",
"      Chan SM, Boisjoly H. Advances in the use of adhesives in ophthalmology. Curr Opin Ophthalmol 2004; 15:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/47\">",
"      Kili&ccedil; A, Ozdengil E. Skin graft fixation by applying cyanoacrylate without any complication. Plast Reconstr Surg 2002; 110:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/48\">",
"      Schwaiger N, Wu J, Wright B, et al. BioWeld(&reg;) Tube and surgical glue for experimental sutureless venous microanastomosis. Br J Surg 2010; 97:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/49\">",
"      Lumsden AB, Heyman ER, Closure Medical Surgical Sealant Study Group. Prospective randomized study evaluating an absorbable cyanoacrylate for use in vascular reconstructions. J Vasc Surg 2006; 44:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/50\">",
"      Testini M, Lissidini G, Poli E, et al. A single-surgeon randomized trial comparing sutures, N-butyl-2-cyanoacrylate and human fibrin glue for mesh fixation during primary inguinal hernia repair. Can J Surg 2010; 53:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/51\">",
"      Petratos PB, Rucker GB, Soslow RA, et al. Evaluation of octylcyanoacrylate for wound repair of clinical circumcision and human skin incisional healing in a nude rat model. J Urol 2002; 167:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/52\">",
"      Ozkan KU, Gonen M, Sahinkanat T, et al. Wound approximation with tissue glue in circumcision. Int J Urol 2005; 12:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/53\">",
"      Cheng W, Saing H. A prospective randomized study of wound approximation with tissue glue in circumcision in children. J Paediatr Child Health 1997; 33:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/54\">",
"      Elemen L, Seyidov TH, Tugay M. The advantages of cyanoacrylate wound closure in circumcision. Pediatr Surg Int 2011; 27:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/55\">",
"      Kaye JD, Kalisvaart JF, Cuda SP, et al. Sutureless and scalpel-free circumcision--more rapid, less expensive and better? J Urol 2010; 184:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/56\">",
"      Zafar F, Thompson JN, Pati J, et al. Sutureless circumcision. Br J Surg 1993; 80:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/57\">",
"      Cain JE Jr, Dryer RF, Barton BR. Evaluation of dural closure techniques. Suture methods, fibrin adhesive sealant, and cyanoacrylate polymer. Spine (Phila Pa 1976) 1988; 13:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/58\">",
"      Epstein NE. Dural repair with four spinal sealants: focused review of the manufacturers' inserts and the current literature. Spine J 2010; 10:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/59\">",
"      Nicotera SP, Decamp MM. Special situations: air leak after lung volume reduction surgery and in ventilated patients. Thorac Surg Clin 2010; 20:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/60\">",
"      Yoo J, Chandarana S, Cosby R. Clinical application of tissue adhesives in soft-tissue surgery of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2008; 16:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/61\">",
"      Pursifull NF, Morey AF. Tissue glues and nonsuturing techniques. Curr Opin Urol 2007; 17:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/62\">",
"      Chao HH, Torchiana DF. BioGlue: albumin/glutaraldehyde sealant in cardiac surgery. J Card Surg 2003; 18:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/63\">",
"      Narakas A. The use of fibrin glue in repair of peripheral nerves. Orthop Clin North Am 1988; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/64\">",
"      Khan H, Chaubey S, Desai J. Early failure of coronary artery bypass grafts: an albumin cross-linked glutaraldehyde (BioGlue) related complication. J Card Surg 2011; 26:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/65\">",
"      Allen MS, Wood DE, Hawkinson RW, et al. Prospective randomized study evaluating a biodegradable polymeric sealant for sealing intraoperative air leaks that occur during pulmonary resection. Ann Thorac Surg 2004; 77:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/66\">",
"      Klijian A. A novel approach to control air leaks in complex lung surgery: a retrospective review. J Cardiothorac Surg 2012; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/67\">",
"      Glickman M, Gheissari A, Money S, et al. A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly than gelfoam/thrombin: results of a randomized controlled trial. Arch Surg 2002; 137:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/68\">",
"      Nakajima M, Kamei T, Tomimatu K, Manabe T. An intraperitoneal tumorous mass caused by granulomas of microfibrillar collagen hemostat (Avitene). Arch Pathol Lab Med 1995; 119:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/69\">",
"      Edmonson MB. Foreign body reactions to dermabond. Am J Emerg Med 2001; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/70\">",
"      Singer AJ, Hollander JE, Valentine SM, et al. Prospective, randomized, controlled trial of tissue adhesive (2-octylcyanoacrylate) vs standard wound closure techniques for laceration repair. Stony Brook Octylcyanoacrylate Study Group. Acad Emerg Med 1998; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/71\">",
"      Toriumi DM, Bagal AA. Cyanoacrylate tissue adhesives for skin closure in the outpatient setting. Otolaryngol Clin North Am 2002; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/72\">",
"      Ferschl MB, Rollins MD. Thromboemboli, acute right heart failure and disseminated intravascular coagulation after intraoperative application of a topical hemostatic matrix. Anesth Analg 2009; 108:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/73\">",
"      Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000; 69:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/74\">",
"      Renkens KL Jr, Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine (Phila Pa 1976) 2001; 26:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/75\">",
"      Hanks JB, Kjaergard HK, Hollingsbee DA. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/76\">",
"      Rousou J, Levitsky S, Gonzalez-Lavin L, et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg 1989; 97:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/77\">",
"      Achneck HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010; 251:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/78\">",
"      Burgert JM, Gegel BT, Austin R 3rd, et al. Effects of arterial blood pressure on rebleeding using Celox and TraumaDEX in a porcine model of lethal femoral injury. AANA J 2010; 78:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/79\">",
"      Finley DS, Lee DI, Eichel L, et al. Fibrin glue-oxidized cellulose sandwich for laparoscopic wedge resection of small renal lesions. J Urol 2005; 173:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17769/abstract/80\">",
"      Krishnan S, Conner TM, Leslie R, et al. Choice of hemostatic agent and hospital length of stay in cardiovascular surgery. Semin Cardiothorac Vasc Anesth 2009; 13:225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15069 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17769=[""].join("\n");
var outline_f17_22_17769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H336520116\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H336519931\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H164152142\">",
"      INDICATIONS FOR USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H801744950\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H801744936\">",
"      AVAILABLE PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709637221\">",
"      Physical agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709637255\">",
"      - Bone wax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709637262\">",
"      - Ostene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709637269\">",
"      - Dry matrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H801744470\">",
"      Oxidized regenerated cellulose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H801744477\">",
"      Gelatin matrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H709637276\">",
"      Microporous polysaccharide spheres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H709637298\">",
"      Microfibrillar collagen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H801744850\">",
"      - External agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709637305\">",
"      Biologically active agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709637521\">",
"      - Topical thrombin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H709637319\">",
"      - Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709637333\">",
"      Tissue adhesives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H336520087\">",
"      ADVERSE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151365\">",
"      Impaired wound healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151386\">",
"      Surgical infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151379\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151399\">",
"      Blood-borne disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151406\">",
"      Vascular thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365552602\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H336520109\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164151169\">",
"      Surgical scenarios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365552979\">",
"      Cost considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H336520116\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15069|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/54/20334\" title=\"table 1\">",
"      Topical hemostatic agents used in surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41478?source=related_link\">",
"      Superficial wound repair with tissue adhesives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17770="Use of intracoronary stents for specific coronary lesions";
var content_f17_22_17770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of intracoronary stents for specific coronary lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/22/17770/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/22/17770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous coronary intervention (PCI) refers to both nonstenting procedures and stent interventions. Stenting represented an advance over percutaneous transluminal coronary angioplasty (PTCA) alone because acute procedural success was higher and the rate of restenosis requiring target lesion revascularization was much lower. Approximately 20 to 30 percent of patients required clinically-driven repeat target lesion revascularization within the first year after PTCA alone compared to 10 to 15 percent with bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-eluting stents (DES) represented a further advance in PCI and are now used in the majority of procedures. In a 2006 meta-analysis of 19 trials of drug-eluting (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) and bare-metal stents in 7060 patients, the rate of target lesion revascularization was reduced by 64 percent with DES (6.2 versus 16.6 percent, OR 0.36, 95% CI 0.31-0.41) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug-eluting intracoronary stents: General principles\", section on 'Efficacy and safety compared to BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of PCI for specific coronary lesions will be reviewed here. The emphasis will be on the outcomes with drug-eluting stents. Issues related to the use of drug-eluting stents, the major clinical trials demonstrating the efficacy of drug-eluting stents compared to bare-metal stents, and the general principles of stent deployment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link\">",
"     \"General principles of the use of intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GUIDELINE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    focused update for PCI recommended use of a drug-eluting stent (DES) as an alternative to bare-metal stents in patients with lesions for which a favorable efficacy and safety profile has been demonstrated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/5\">",
"     5",
"    </a>",
"    ]. Use of a drug-eluting stent with other lesions could be considered but the efficacy was less well established.",
"   </p>",
"   <p>",
"    Patients with DES may require more prolonged dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker because of a possible increased risk of late stent thrombosis, especially if therapy is interrupted for noncardiac surgery. As a result, a bare-metal stent or balloon angioplasty was recommended for those patients in whom surgical or invasive procedures were likely in the 12 months following DES implantation. The importance of antiplatelet therapy to prevent stent thrombosis and recommended regimens with the different types of stents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The focused update also emphasized the importance of a discussion with the patient by the interventional cardiologist regarding the need for and duration of dual antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIFIC CORONARY LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left main and left anterior descending disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left main, left main equivalent, and proximal left anterior descending disease are associated with a relatively large amount of myocardium at risk. The possible indications for efficacy of DES with these lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of significant proximal left anterior descending coronary artery disease\", section on 'PCI versus CABG'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H2733901#H2733901\">",
"     \"Management of left main coronary artery disease\", section on 'DES versus BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Multivessel revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG has been preferred to PCI with stenting in patients who have a large amount of myocardium at risk due to significant left main disease, diffuse triple vessel disease, or two vessel disease with significant involvement of the LAD artery. This preference is due in part to a much higher rate of repeat target vessel revascularization with bare-metal stents compared to CABG (eg, 21 versus 4 percent at one year, 27 versus 7 percent at three years in the ARTS I trial of patients with multivessel disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this difference may diminish with DES. The ARTS II registry was designed to compare the outcomes with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stent in 607 patients with multivessel coronary artery disease to the outcomes in the ARTS I trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/7\">",
"     7",
"    </a>",
"    ]. At one year, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of major adverse cardiac and cerebrovascular events (MACCE) in ARTS II was similar to that of the CABG arm in ARTS I and significantly lower than in the PCI with bare-metal stent arm in ARTS I (10.4 and 11.6 versus 26.5 percent). After adjustment for risk factors, the rate of MACCE was lower with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -stent in ARTS II than with CABG in ARTS I (8.1 versus 13.1 percent).",
"     </li>",
"     <li>",
"      The rate of revascularization was 8.5 percent in ARTS II compared to 4.1 percent with CABG in ARTS I and 21.3 percent with PCI in ARTS I. The difference in the rate of revascularization rate between the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      stent in ARTS II and CABG in ARTS I was greater in the subset of patients with diabetes (12.6 versus 4.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment assignment was not randomized as the CABG-control patients were historical (from the ARTS I trial). As a result, comparison of the two groups should be made with caution and firm conclusions cannot be drawn.",
"   </p>",
"   <p>",
"    It seems likely that drug-eluting stents will increase the role of PCI in patients previously considered to be candidates for CABG. However, although drug-eluting stents markedly reduce the rate of target vessel revascularization, the rate is still somewhat higher than with CABG in the short term (one to two years) as shown in ARTS II [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/7\">",
"     7",
"    </a>",
"    ] and in an observational study of OP CABG (6.6 versus 0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H13#H13\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'ARTS I trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Potential concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are potential concerns with multivessel and complex lesion treatment with drug-eluting stents that may limit its use compared to CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in the 30-day rate of myocardial infarction (MI), mostly periprocedural and non-Q wave, was observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents (8.3 versus 3.3 percent with bare-metal stents) in the TAXUS V trial [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/11\">",
"       11",
"      </a>",
"      ]. The paclitaxel stent continued to demonstrate a significant reduction in target lesion revascularization compared with the bare-metal stent (12.6 versus 28.2 percent).",
"     </li>",
"     <li>",
"      A high risk of subacute and late stent thrombosis (5 of 17 [29 percent] in one series) in patients who prematurely discontinue antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A more pronounced increase in revascularization rate compared to CABG in diabetic patients (12.6 versus 4.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A greater likelihood that such patients will have progressive coronary disease in areas not protected by stenting. In a review of 3747 PCIs from the National Heart, Lung, and Blood Institute Dynamic Registry, 216 (5.8 percent) required nontarget lesion PCI at one year: 87 percent of these nontarget lesions were &le;60 percent stenosis at initial PCI (mean 42 percent compared to 84 percent during the recurrent event) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A greater likelihood of incomplete revascularization after PCI compared to CABG, particularly in patients with decrease left ventricular systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149378448\">",
"    <span class=\"h3\">",
"     Complete versus incomplete revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concerns raised in the section above result, at least in part, from attempts to completely revascularize the coronary circulation using PCI in a manner similar to that done with CABG. The concept that complete revascularization (CR) leads to better outcomes than incomplete revascularization (IR) was based on outcomes seen in older CABG studies and predate modern medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H23#H23\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Incomplete revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypothesis that CR is superior has been challenged by more recent studies performed in patients on optimal medical therapy and who receive current CABG and PCI techniques, including drug-eluting stents (DES). Early studies of comparing IR to CR in patients undergoing stenting found higher rates of death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and the need for repeat revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/17\">",
"     17",
"    </a>",
"    ]. Most, but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/16\">",
"     16",
"    </a>",
"    ], of these studies were in patients who received bare metal stents.",
"   </p>",
"   <p>",
"    Outcomes after CR and IR were compared in a single-center registry report of 1914 patients undergoing PCI (n=1400) with DES or CABG (n=514) for multivessel CAD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/18\">",
"     18",
"    </a>",
"    ]. CR was achieved in 41 percent and 67 percent of those receiving PCI or CABG, respectively. Using a definition of CR (applied to the diagnostic angiogram) as any attempt to revascularize all disease segments &ge;1.5 mm, no significant difference between those with CR and those with IR in the adjusted rates of five year death (8.9 versus 8.9 percent; adjusted hazard ratio 1.04, 95% CI 0.76-1.43 respectively) or the composite of death, MI, or stroke (12.1 versus 11.9; adjusted hazard ratio 1.04 95% CI 0.79-1.36). The results were similar for analyses performed on only those patients who underwent PCI.",
"   </p>",
"   <p>",
"    Based on the available evidence, we suggest that, for patients with multivessel disease undergoing PCI due to angina refractory to medical therapy, an attempt be made to revascularize all lesions likely to impair coronary flow to moderate or large areas of viable myocardium. The results of non-invasive imaging techniques performed before PCI or the determination of fractional flow reserve during the procedure may be useful in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Multivessel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ostial lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ostial lesions respond poorly to conventional balloon PTCA because of inadequate dilation and elastic recoil. Stents may be an excellent treatment for elastic recoil, but efficacy is uncertain if debulking is also required.",
"   </p>",
"   <p>",
"    Implantation must be precise to avoid positioning the stent too proximally, while assuring adequate coverage of ostial disease. Lack of optimal positioning can result in stent protrusion into the aorta, which may make repeat catheterization difficult or increase the risk for thromboembolic complications.",
"   </p>",
"   <p>",
"    Data are limited on DES for ostial lesions but the benefit appears to be similar to that seen with other lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The best data come from the SCANDSTENT trial in which 322 patients with symptomatic complex coronary artery disease were randomly assigned to PCI with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting or bare-metal stent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 73 patients with ostial lesions, target lesion revascularization by seven months occurred only with bare-metal stents (0 versus 35 percent). In our experience, drug-eluting stenting of the RCA ostium has been associated with a higher frequency of clinically significant restenosis relative to other locations.",
"   </p>",
"   <p>",
"    Lesions at the origin of the left anterior descending artery were evaluated in a study comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents in 68 consecutive patients with such lesions to 77 patients treated with BMS during the preceding two years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/22\">",
"     22",
"    </a>",
"    ]. Positioning of the sirolimus stent into the distal left main trunk was required in one-third of patients for complete lesion coverage. The sirolimus stent was associated with significant reductions in angiographic restenosis at six months (5 versus 32 percent with BMS) and target vessel revascularization at one year (0 versus 17 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic total occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among all patients who undergo coronary arteriography, chronic total occlusion (CTO), defined as either TIMI grade 0 flow (true total occlusion) or TIMI grade 1 flow (functional total occlusion), is present in at least one coronary artery in approximately one-third [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Among patients who have had an acute ST elevation MI who were treated with reperfusion therapy in clinical trials, CTO was present in as many as 30 percent at three to six months after thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/25\">",
"     25",
"    </a>",
"    ] and approximately 6 percent at six months after primary PCI with stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary barrier to PCI for CTO has been procedural failure due to an inability to cross the CTO with either the guidewire or, much less often, the balloon angioplasty catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Risk factors for failure include CTO length &gt;15 mm or not measurable, moderate to severe calcification, and lesion duration &ge;180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial large PCI studies noted a procedural success rate of approximately 75 percent with CTO [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/23,28-31\">",
"     23,28-31",
"    </a>",
"    ]. Increasing experience and improved technology (eg, stiffer guidewires) has increased the success rate to 80 to 90 percent with experienced operators [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. If the guidewire can be passed into the distal true lumen, dilating and stenting with drug-eluting stents is typically straightforward and durable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of periprocedural major adverse cardiovascular events after successful PCI does not appear to be higher than with non-CTO lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/30\">",
"     30",
"    </a>",
"    ]. However, failed procedures are associated with higher rates of MI, the need for CABG, and long-term mortality, and a lower rate of freedom from angina [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although better outcomes were achieved with bare-metal stenting compared to angioplasty alone, the rate of restenosis remained quite high [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27,33,34\">",
"     27,33,34",
"    </a>",
"    ]. A meta-analysis evaluated nine trials in which 1409 patients with CTO were randomly assigned to PTCA alone or with bare-metal stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/33\">",
"     33",
"    </a>",
"    ]. Stenting was associated with significant reductions in the rates of reocclusion (7 versus 16 percent with PTCA), angiographic restenosis (41 versus 61 percent), and target lesion or target vessel revascularization (17 versus 32 percent).",
"   </p>",
"   <p>",
"    Data from the two randomized trials illustrate the superiority of DES for CTO:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PRISON II trial evaluated the six-month outcomes in 200 patients with CTO randomly assigned to either a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or bare-metal stent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/35\">",
"       35",
"      </a>",
"      ]. The sirolimus stent was associated with significant reductions in the rate of in-segment restenosis (11 percent versus 41 percent) and target lesion revascularization (4 versus 19 percent).",
"     </li>",
"     <li>",
"      In a subset analysis of 115 patients with CTO in the SCANDSTENT trial of patients with symptomatic complex coronary artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/20\">",
"       20",
"      </a>",
"      ], target lesion revascularization by seven months occurred only in patients who received bare-metal stents (0 versus 32 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar benefits have been noted in observational studies with both the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. As a result, drug-eluting stents are now routinely used for PCI of CTO [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the demonstrated good outcomes with DES, CTO was considered an indication for bypass surgery. In the BARI trial of PCI versus CABG and a 2004 report from the Mayo Clinic, CTO accounted for 68 to 75 percent of lesions that were considered not amenable to PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 European Society of Cardiology task force on PCI concluded that the weight of evidence was in favor of efficacy of PCI in CTO if the occlusion can be crossed with a guidewire [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/42\">",
"     42",
"    </a>",
"    ]. The task force also suggested that, until proven otherwise, PCI (rather than CABG) should be performed only with reservation in diabetic patients with multivessel disease and in patients with unprotected left main lesions. It was acknowledged that these limitations to PCI may change with increasing experience with drug-eluting stents.",
"   </p>",
"   <p>",
"    A 2005 consensus document concluded that, when CTO represents the only significant coronary lesion, PCI is warranted when all three of the following conditions are met [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occluded vessel is responsible for the patient's symptoms or in selected patients with silent ischemia in whom there is a large amount of myocardium at risk",
"     </li>",
"     <li>",
"      The myocardial territory of the occluded artery is viable",
"     </li>",
"     <li>",
"      The likelihood of success is &gt;60 percent with estimated rate of death and MI less than 1 percent and less than 5 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with multivessel disease and one or more CTOs, any of the following favors surgical revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left main disease",
"     </li>",
"     <li>",
"      Complex three-vessel disease, particularly in patients with insulin-requiring diabetes, severe left ventricular dysfunction, or chronic kidney disease",
"     </li>",
"     <li>",
"      An occluded proximal LAD that supplies a viable anterior wall that is not favorable for PCI",
"     </li>",
"     <li>",
"      Multiple CTOs with a low anticipated rate of success",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patients can be managed by PCI with the goal being complete revascularization, if possible. The nonoccluded vessels should be stented first if there is a low anticipated rate of complications. In contrast, PCI should usually be performed first on the CTO if failed PCI of this lesion would lead to referral for CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long lesions or diffuse disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long stents or multiple stents may play an important role in the treatment of long lesions or diffuse disease. Restenosis rates are proportionally higher in longer lesions, but are lower than those associated with conventional PTCA. With bare-metal stents, longer stent segment length (&gt;35 mm) is associated with an increased risk of restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/43\">",
"     43",
"    </a>",
"    ]. Although DES reduce the rate of restenosis, stent length &gt;35 mm is still a risk factor for restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stent length should also be viewed in terms of lesion length. In the TAXUS IV trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents, the operators were instructed to choose stent lengths to cover the lesion by 2 to 4 mm at each margin. Using longer stent to lesion lengths beyond that required to achieve this goal was of no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/45\">",
"     45",
"    </a>",
"    ]. In the SIRIUS trial, excess stent length was associated with an increased risk for restenosis; the absolute increase in follow-up diameter stenosis per 10 mm excess stent length was 3.6 and 2.1 percent for bare-metal and DES, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Overlapping stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential concern with longer lesion treatment is that overlapping DES may result in adverse effects due to possible drug toxicity or polymer instability in the overlap segment. However, the use of multiple overlapping DES for very long lesions was relatively safe and associated with good intermediate-term outcomes in two small series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of these reports, 66 patients with diffuse disease of the left anterior descending artery (average lesion length about 80 mm) were treated with multiple (mean 2.8)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiographic and procedural success was achieved in 95 percent of patients.",
"     </li>",
"     <li>",
"      Eleven patients (17 percent) developed a non-ST elevation MI in hospital, and one patient developed stent thrombosis.",
"     </li>",
"     <li>",
"      At follow-up angiography at six months in 52 patients, 10 (19.6 percent) had restenosis; most of the lesions were focal.",
"     </li>",
"     <li>",
"      At an average follow-up of 13.6 months, there were no deaths, one patient had a non-ST elevation MI, 10 (15 percent) required target vessel revascularization, and one patient required CABG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overlapping stents are associated with greater late lumen loss and more frequent angiographic restenosis than single stents. However, a subset analysis from three randomized trials and two prospective observational studies comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    to bare-metal stents found that the magnitude of the restenosis benefit of sirolimus stents was similar in overlapping and single stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns have been raised about possible persistent inflammation and delayed reendothelialization at overlapping compared to nonoverlapping sites. A pathologic study in a rabbit iliac artery model of overlapping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents found evidence for increased inflammation and delayed healing for drug-eluting compared with bare-metal stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/50\">",
"     50",
"    </a>",
"    ]. These changes were more pronounced at overlapping than nonoverlapping sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Very long lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of drug-eluting stents for very long lesions (median 79 mm, range 64 to 168 mm) was evaluated in a series of 122 patients with de novo lesions; multiple overlapping stents were used (mean 3.3 per lesion), an approach that has been called \"full metal jacket\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/51\">",
"     51",
"    </a>",
"    ]. Periprocedural MI occurred in two patients (1.6 percent). At one year, the overall rate of major adverse cardiac events was 18 percent, including target vessel revascularization in only 7.5 percent, nonfatal MI in 8.2 percent, and death in 4.1 percent. There was only one cases of subacute stent thrombosis and the outcomes were similar with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bifurcation lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bifurcation lesions can be defined as stenoses involving the origin of an arterial side branch that is &ge;2.0 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These lesions are more difficult to treat due in part to differences in anatomic patterns of stenosis, variations in the diameter of each of the branches, and the angle at which the side branch comes off the main branch. In addition, the degree of ostial side branch stenosis is the primary determinant of the need for side branch protection.",
"   </p>",
"   <p>",
"    Treatment of bifurcation lesions with stenting has been associated with an increase in early complications, including compromise of the branch vessel or the target lesion and enhanced potential for restenosis involving either the parent vessel or side branch. In addition, stenting may impair access to the side branch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     DES versus BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, PCI with DES is performed in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/54\">",
"     54",
"    </a>",
"    ]. In selected patients, a debulking procedure such as directional or rotational atherectomy is combined with drug-eluting stenting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only randomized trial data comparing drug-eluting and bare-metal stents in bifurcation lesions come from the SCANDSTENT trial of patients with symptomatic complex coronary artery disease cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/20\">",
"     20",
"    </a>",
"    ]. Among the 109 patients with bifurcation lesions, the rate of target lesion revascularization by seven months was much lower with DES than with bare-metal stents (7 versus 29 percent). The target lesion revascularization rate with bare-metal stents in SCANDSTENT was similar to that noted in prior studies (17 to 37 percent at six to twelve months) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/53,55,56\">",
"     53,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Main versus main plus side branch stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence supports a strategy of main vessel only stenting with provisional stenting of the side branch [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Three randomized trials, each using somewhat different techniques, have compared simple (main vessel only with an option for side branch stenting) to complex (main plus side branch) stenting with DES. Two of these trials reported no significant differences between the approaches using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], while the third found worse outcomes with the complex procedure using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/60\">",
"     60",
"    </a>",
"    ]. Comparing complex to simple techniques, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Nordic Bifurcation trial of 413 patients, there was no significant difference in the rate of major adverse cardiac events (death, MI target vessel revascularization, or stent thrombosis) between the groups (3.4 versus 2.9 percent, respectively) at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CACTUS trial of 350 patients, there was no significant difference in the rate major adverse cardiac events (death, MI, and target vessel revascularization) between the two groups (15.8 versus 15 percent respectively) at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the BBC ONE trial of 500 patients, the primary endpoint (a composite of death, MI, and target-vessel failure) occurred significantly more often in the complex group (15.2 versus 8.0 percent; hazard ratio 2.20, 95% CI 1.17-3.47), attributable principally to a significantly higher rate of MI (11.2 versus 3.6 percent) at nine months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these three trials, patients assigned to complex procedures had statistically longer procedure and fluoroscopy times, higher contrast volumes, and higher rates of procedure-related increases in biomarkers of myocardial injury.",
"   </p>",
"   <p>",
"    Based upon the available evidence, including the fact that most side branches have a normal fractional flow reserve and presumed good outcome irrespective of angiographic severity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/61\">",
"     61",
"    </a>",
"    ], we recommend a strategy of limiting stent implantation to the main vessel using a drug-eluting stent for patients with bifurcation lesions. Side branch stent placement is appropriate for significant dissection, reduced flow (Thrombolysis in Myocardial Infarction flow less than grade 3), or clinical evidence of ischemia. An exception to this approach may be patients in whom the side branch is particularly large, in which case a two-stent approach may be preferable.",
"   </p>",
"   <p>",
"    Other stents are being evaluated for the treatment of bifurcation lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/62\">",
"     62",
"    </a>",
"    ]. One such stent, the Axxess self-expanding, drug-eluting (biolimus A9) stent, is designed to allow easy access into the side branch by covering the first portion of the side branch in addition to the parent vessel. It appears safe and effective in early clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180724888\">",
"    <span class=\"h4\">",
"     Final kissing balloon dilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether simultaneous balloon dilatation of both the main vessel and the side branch (final kissing balloon dilatation) is necessary after placement of a stent in the main vessel was addressed in the Nordic-Baltic Bifurcation Study III [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/64\">",
"     64",
"    </a>",
"    ]. In this trial, 477 patients with either stable or unstable disease and a bifurcation lesion were randomly assigned to either final kissing balloon dilatation (FKBD) or no FKBD after stenting of the main vessel. Stenting of the side branch was allowed if, after FKBD, side branch TIMI flow grade was less than 3 (ie, less than normal flow which fills the distal bed completely). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link&amp;anchor=H2#H2\">",
"     \"Coronary artery patency and outcome after myocardial infarction\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At six months, there was no significant difference in the rate of the primary composite endpoint (cardiac death, nonprocedure related index lesion myocardial infarction, target lesion revascularization, or definite stent thrombosis) between the FKBD and no FKBD groups (2.1 and 2.5 percent, respectively). As expected, based upon the experience comparing main versus main plus side branch stenting discussed in the preceding section, FKBD resulted in increased use of contrast media and longer procedure and fluoroscopy times.",
"   </p>",
"   <p>",
"    We suggest FKBD only in cases where there is reduced flow or other evidence of ischemic compromise involving a side branch that supplies at least a moderate myocardial territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Side branch stenting techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the side branch is stented, a variety of techniques have been utilized and are discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/54\">",
"     54",
"    </a>",
"    ]. Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The simplest is provisional side branch stenting, in which a single stent is placed in the main vessel, and balloon dilation or stenting of the side branch is performed only if branch compromise ensues.",
"     </li>",
"     <li>",
"      Preemptive stenting of both the main vessel and side branch, either by simultaneous inflation of the two stents side by side over a short distance proximal to the bifurcation (simultaneous kissing stents), \"culotte\" technique, in which a second stent is deployed through a strut of an initially placed stent in the parent vessel of side branch, overlapping the first stent for a short distance, or a variety of so-called \"T\" or \"Y\" techniques.",
"     </li>",
"     <li>",
"      In the crush technique, the proximal end of the stent in the side branch is crushed against the vessel wall as the second stent is deployed in the parent vessel in an attempt to optimize stent coverage of the entire plaque surface at the carina [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/52,65-67\">",
"       52,65-67",
"      </a>",
"      ]. A final kissing balloon postdilation (FKB) is then usually performed by readvancing a guidewire and angioplasty balloon through the sides of the parent vessel stent into the side branch and inflating simultaneously with a second balloon positioned within the parent stent. Most investigators have abandoned the technique due to lack of demonstrated benefit, possible increased safety concerns, and uncertainty of achieving final kissing balloon inflation in all cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus for which of the other two stent techniques are preferred in the treatment of bifurcation lesions, since none have been shown to be superior to stenting of the main branch and rescue of the side branch with balloon angioplasty as needed. It is our practice to avoid side branch stents whenever possible. Regardless of technique, we recommend final kissing balloon inflation for optimal stent deployment whenever side branch stenting is required. Development of specially designed bifurcation stents may offer promise in the treatment of these complex lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Left main disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with left main disease, a distal bifurcation lesion requiring a two stent approach is associated with higher rates of angiographic restenosis and target lesion revascularization after PCI with drug-eluting stents. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=see_link&amp;anchor=H2733901#H2733901\">",
"     \"Management of left main coronary artery disease\", section on 'DES versus BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Small coronary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials before the availability of drug-eluting stents suggested that bare-metal stenting in small coronary arteries did not improve long-term outcomes compared to conventional PTCA provided that dilatation produced a satisfactory initial result [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/68\">",
"     68",
"    </a>",
"    ]. Stents were beneficial if the results of balloon PTCA were suboptimal with a persistent significant residual stenosis.",
"   </p>",
"   <p>",
"    The efficacy of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stent compared to bare-metal stents in small coronary arteries was evaluated in two randomized trials &mdash; E-SIRIUS and SES-SMART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In E-SIRIUS, 352 patients with long lesions (15 to 32 mm) in small coronary arteries (mean 2.55 mm) were randomly assigned to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or bare-metal stent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/69\">",
"       69",
"      </a>",
"      ]. At eight to nine months, sirolimus stenting was associated with significant reductions in restenosis within the lesion &ge;50 percent diameter (6 versus 42 percent) and the rate of target vessel revascularization (4 versus 21 percent).",
"     </li>",
"     <li>",
"      Similar benefits were noted in the SES-SMART trial in which 257 patients with a de novo stenosis in a small coronary segment (diameter &le;2.75 mm, mean 2.20 mm) were randomly assigned to receive a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stent (SES) or a bare-metal stent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/70\">",
"       70",
"      </a>",
"      ]. At eight months, the sirolimus stent was associated with significant reductions in the rates of angiographic restenosis (primary outcome) in the treated segment (10 versus 53 percent), target lesion revascularization (7 versus 21 percent), and MI (1.6 versus 7.8 percent). While restenosis risks in the two patient groups were not equivalent (more patients in the sirolimus group had diabetes), stratified and multivariable analyses confirmed an independent reduction in restenosis risk with the sirolimus stent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/71\">",
"       71",
"      </a>",
"      ]. At 24-month follow-up, the composite clinical endpoint (death, non-fatal MI, ischemia-driven target lesion revascularization, and cerebrovascular accidents) was significantly lower with the SES (12.6 versus 33.1 percent; hazard ratio 0.30, 95% CI 0.17-0.55) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/72\">",
"       72",
"      </a>",
"      ]. This was attributable principally to a greater reduction in revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefit was also noted in subset analysis of the TAXUS V trial, which in part compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and bare-metal stents in complex lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the 203 patients with small coronary arteries (mean diameter 2.08 mm), the paclitaxel stent was associated at nine months with significant reductions in angiographic restenosis (31.2 versus 49.4 percent) and target lesion revascularization (10.4 versus 21.5 percent).",
"   </p>",
"   <p>",
"    The above observations demonstrate that drug-eluting stents improve target lesion revascularization rates compared to bare-metal stents in small vessels. However, the absolute rates in small vessels are still higher than in larger vessels. This was illustrated in a nonrandomized study of 2058 patients who received either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    stent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/73\">",
"     73",
"    </a>",
"    ]. The rates of target lesion revascularization for the three tertiles evaluated (&le;2.41, 2.41 to 2.84 and &gt;2.84 mm in diameter) were 12.1, 8.4, and 8.0 percent, respectively.",
"   </p>",
"   <p>",
"    A separate issue is the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    stents for lesions in small coronary arteries. There appears to be an increase in the need for target lesion revascularization with paclitaxel stents as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ISAR-SMART 3 trial directly compared the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stents in 360 patients undergoing PCI for de novo lesions in native coronary arteries with a diameter less than 2.80 mm (mean 2.42 mm) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/74\">",
"       74",
"      </a>",
"      ]. At follow-up, paclitaxel stents were associated with significant increases in the primary endpoint of late luminal loss (0.56 versus 0.25 mm) and in the secondary endpoints of binary angiographic restenosis (19.0 versus 11.4 percent) and target lesion revascularization (14.7 versus 6.6 percent). There was no difference between the groups in death or MI at one year.",
"     </li>",
"     <li>",
"      In a retrospective review of 2058 consecutive patients treated with either a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      or a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      stent, target vessel revascularization at nine months was significantly lower with the sirolimus stent in vessels in the lowest tertile of vessel diameter (&le;2.41 mm, 8.6 versus 16.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/73\">",
"       73",
"      </a>",
"      ]. There was no significant difference in outcomes in vessels in the other tertiles.",
"     </li>",
"     <li>",
"      In a non-prespecified, subgroup analysis from the SIRTAX trial, SES reduced the composite primary endpoint (cardiac death, MI, or ischemia driven target lesion revascularization) to a significantly greater extent than PES at two year follow-up only in patients with all treated vessels &le;2.75 mm in diameter (10.4 versus 21.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/75\">",
"       75",
"      </a>",
"      ]. This finding was driven mainly by a significant reduction in target lesion revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Large coronary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating outcomes in patients with large coronary arteries (&ge;3.0 mm in diameter), two points should be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of target lesion revascularization (TLR) is lower in large compared to small coronary arteries after stenting with either BMS or DES [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/76-79\">",
"       76-79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the broad population of patients who undergo PCI with stenting, DES reduce the rate of target lesion revascularization (TLR) compared to BMS, while the risks of death and MI are similar. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348517385#H348517385\">",
"       \"Drug-eluting compared to bare metal intracoronary stents\", section on 'DES compared to BMS'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the subset of patients with large coronary arteries (&ge;3.0 mm in diameter), we believe evidence allows for the following conclusions regarding efficacy and safety comparing DES to BMS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of TLR is equivalent or lower with DES compared to BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/11,79,80\">",
"       11,79,80",
"      </a>",
"      ], but the lower TLR rate in larger vessels makes the absolute benefits lower.",
"     </li>",
"     <li>",
"      The issue of the relative rate of harm between DES and BMS has not been adequately addressed.",
"      <br/>",
"      <br/>",
"      As the benefit from a reduction in TLR with DES compared to BMS declines in large vessels, any potential increase in risk associated with the use of DES becomes increasingly important. Retrospective analyses have raised the possibility of a possible increase in risk (cardiac death or MI) with DES in these vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/80-82\">",
"       80-82",
"      </a>",
"      ]. The BASKET-PROVE trial attempted to directly address this issue by randomly assigning 2314 patients needing stents 3.0 mm or greater in diameter to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stents (SES), everolimus-eluting stents (EES), or BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/22/17770/abstract/83\">",
"       83",
"      </a>",
"      ]. While the rate of the primary endpoint (composite of death from cardiac causes or nonfatal myocardial infarction at two years) was",
"      <strong>",
"       lower",
"      </strong>",
"      with the two DES (2.6 verus 3.2 versus 4.8 percent for SES, EES, and BMS respectively), these differences did not achieve statistical significance. This was due in part to unexpectedly low event rates, causing the trial to be underpowered to address the issue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute vessel closure or dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenting is the treatment of choice for either acute or threatened closure complicating PTCA and for the treatment of dissection; the goal is to restore TIMI 3 flow. In addition, acute or threatened closure may complicate predilation, stent deployment, or postdilation during a planned stent procedure and require the placements of additional stents to achieve optimal results. Failure to adequately restore flow or leaving untreated dissections significantly increases the risk for subacute thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H9#H9\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Dissection and abrupt closure after PTCA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For treatment of acute closure or extensive dissections, the operator must consider other factors that may jeopardize the final result, including the relative size of the vessel, the inflow of blood into the treated segment, and the distal runoff. When either the flow into the artery or distal runoff is compromised, there is an increased risk for acute and subacute stent thrombosis, which may negate the beneficial effects of additional stenting. Smaller caliber vessels treated with smaller diameter stents also have an increased likelihood for subacute thrombosis compared to larger vessels treated with larger diameter stents.",
"   </p>",
"   <p>",
"    Emergency surgery may be required in some situations such as dissection of the left main artery or significant bifurcations, refractory thrombosis, loss of guide wire access, or inability to perform stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their use for specific coronary artery lesions, intracoronary stents, particularly DES, have been used in specific clinical settings in addition with stable or unstable angina. Their efficacy in these settings is discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saphenous vein graft stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H12#H12\">",
"       \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Intracoronary stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In-stent restenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H23#H23\">",
"       \"Intracoronary stent restenosis\", section on 'Repeat stenting in bare-metal stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary PCI for ST elevation myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H24756048#H24756048\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Selection of stent type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Non-ST elevation acute coronary syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetic patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H11#H11\">",
"       \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Stent type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=see_link\">",
"       \"Management of coronary heart disease in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) are now used in the majority of percutaneous coronary intervention (PCI) procedures, as they significantly reduce the risk of target lesion revascularization compared to bare-metal stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug-eluting intracoronary stents: General principles\", section on 'Efficacy and safety compared to BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This benefit of DES has been demonstrated in a broad array of lesion types including multivessel, ostial, chronic total occlusion, and long lesions, as well as in small coronary arteries. However, coronary artery bypass graft surgery should be considered in some patients such as those with a high risk of coronary artery stent thrombosis and lesions that cannot be adequately revascularized with PCI, as well as some patients with diabetes or left main coronary artery disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Specific coronary lesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to specific lesion types, DES are of benefit in specific clinical situations such as in patients with diabetes, acute coronary syndromes, vein graft lesions, and in-stent restenosis. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Specific clinical settings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On the other hand, large vessels, especially with focal lesions in patients without diabetes, have lower risk for restenosis and may benefit less from DES. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Large coronary arteries'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8955332\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/1\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/2\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/3\">",
"      Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/4\">",
"      Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006; 92:641.",
"     </a>",
"    </li>",
"    <li>",
"     King, SB, Smith, SC, Hirshfeld, JW Jr, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for PCI. Circulation 2008; 117:e1. Available at: file://circ.ahajournals.org (accessed January 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/6\">",
"      Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004; 109:1114.",
"     </a>",
"    </li>",
"    <li>",
"     Gruberg, L. ARTS II: Arterial Revascularization Therapies Study Part II &ndash; Sirolimus-Eluting Stents vs PCI and CABG at 1 Year www.medscape.com/viewarticle/501424 (Accessed on December 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/8\">",
"      Macaya, C, Garcia, H, Serruys, P, et al. Sirolimus-eluting stents versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease&mdash;a comparison between ARTS I and ARTS II (abstract). Circulation 2005; 112:II-655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/9\">",
"      Herz I, Moshkovitz Y, Hendler A, et al. Revascularization of left anterior descending artery with drug-eluting stents: comparison with off-pump surgery. Ann Thorac Surg 2005; 79:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/10\">",
"      Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/11\">",
"      Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/12\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/13\">",
"      Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/14\">",
"      Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J 2010; 159:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/15\">",
"      Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/16\">",
"      Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/17\">",
"      van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/18\">",
"      Kim YH, Park DW, Lee JY, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011; 123:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/19\">",
"      Dauerman HL. Reasonable incomplete revascularization. Circulation 2011; 123:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/20\">",
"      Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006; 47:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/21\">",
"      Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol 2004; 44:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/22\">",
"      Seung KB, Kim YH, Park DW, et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005; 46:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/23\">",
"      Stone GW, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005; 112:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/24\">",
"      Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J 1993; 126:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/25\">",
"      Veen G, Meyer A, Verheugt FW, et al. Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. J Am Coll Cardiol 1993; 22:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/26\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/27\">",
"      Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/28\">",
"      Kinoshita I, Katoh O, Nariyama J, et al. Coronary angioplasty of chronic total occlusions with bridging collateral vessels: immediate and follow-up outcome from a large single-center experience. J Am Coll Cardiol 1995; 26:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/29\">",
"      Olivari Z, Rubartelli P, Piscione F, et al. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol 2003; 41:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/30\">",
"      Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001; 38:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/31\">",
"      Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J 2005; 26:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/32\">",
"      Baim DS, Kwong RY. Is magnetic resonance image guidance the key to opening chronic total occlusions? Circulation 2006; 113:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/33\">",
"      Agostoni P, Valgimigli M, Biondi-Zoccai GG, et al. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. Am Heart J 2006; 151:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/34\">",
"      Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999; 100:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/35\">",
"      Suttorp MJ, Laarman GJ, Rahel BM, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006; 114:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/36\">",
"      Ge L, Iakovou I, Cosgrave J, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005; 26:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/37\">",
"      Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 2004; 43:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/38\">",
"      Werner GS, Krack A, Schwarz G, et al. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 2004; 44:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/39\">",
"      Nakamura S, Muthusamy TS, Bae JH, et al. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol 2005; 95:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/40\">",
"      Powell BD, Rihal CS, Bell MR, et al. Anticipated impact of drug-eluting stents on referral patterns for coronary artery bypass graft surgery: a population-based angiographic analysis. Mayo Clin Proc 2004; 79:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/41\">",
"      Bourassa MG, Roubin GS, Detre KM, et al. Bypass Angioplasty Revascularization Investigation: patient screening, selection, and recruitment. Am J Cardiol 1995; 75:3C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/42\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/43\">",
"      Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/44\">",
"      Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/45\">",
"      Wong SC, Hong MK, Ellis SG, et al. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). Am J Cardiol 2005; 95:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/46\">",
"      Mauri L, O'Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005; 95:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/47\">",
"      Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005; 45:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/48\">",
"      Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004; 93:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/49\">",
"      Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 2006; 48:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/50\">",
"      Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/51\">",
"      Aoki J, Ong AT, Rodriguez Granillo GA, et al. \"Full metal jacket\" (stented length &gt; or =64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005; 150:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/52\">",
"      Williams DO, Abbott JD. Bifurcation intervention: is it crush time yet? J Am Coll Cardiol 2005; 46:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/53\">",
"      Garot P, Lef&egrave;vre T, Savage M, et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005; 46:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/54\">",
"      Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/55\">",
"      Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol 2000; 35:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/56\">",
"      Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions: two stents versus one stent--immediate and follow-up results. J Am Coll Cardiol 2000; 35:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/57\">",
"      Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/58\">",
"      Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006; 114:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/59\">",
"      Colombo A, Bramucci E, Sacc&agrave; S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009; 119:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/60\">",
"      Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010; 121:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/61\">",
"      Koo BK, Kang HJ, Youn TJ, et al. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol 2005; 46:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/62\">",
"      Latib A, Colombo A, Sangiorgi GM. Bifurcation stenting: current strategies and new devices. Heart 2009; 95:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/63\">",
"      Verheye S, Agostoni P, Dubois CL, et al. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol 2009; 53:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/64\">",
"      Niemel&auml; M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 2011; 123:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/65\">",
"      Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005; 46:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/66\">",
"      Costa RA, Mintz GS, Carlier SG, et al. Bifurcation coronary lesions treated with the \"crush\" technique: an intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/67\">",
"      Moussa I, Costa RA, Leon MB, et al. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the \"crush technique\". Am J Cardiol 2006; 97:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/68\">",
"      Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 2005; 26:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/69\">",
"      Schofer J, Schl&uuml;ter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/70\">",
"      Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/71\">",
"      Holmes DR Jr. Stenting small coronary arteries: works in progress. JAMA 2004; 292:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/72\">",
"      Menozzi A, Solinas E, Ortolani P, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J 2009; 30:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/73\">",
"      Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/74\">",
"      Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/75\">",
"      Togni M, Eber S, Widmer J, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/76\">",
"      Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/77\">",
"      Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/78\">",
"      Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/79\">",
"      Steinberg DH, Mishra S, Javaid A, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (&gt; or =3.5 mm) coronary arteries. Am J Cardiol 2007; 99:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/80\">",
"      Brunner-La Rocca HP, Kaiser C, Pfisterer M, BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/81\">",
"      Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/82\">",
"      Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/22/17770/abstract/83\">",
"      Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363:2310.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1571 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17770=[""].join("\n");
var outline_f17_22_17770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GUIDELINE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIFIC CORONARY LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left main and left anterior descending disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Multivessel revascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Potential concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H149378448\">",
"      - Complete versus incomplete revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ostial lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic total occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long lesions or diffuse disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Overlapping stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Very long lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bifurcation lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - DES versus BMS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Main versus main plus side branch stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H180724888\">",
"      Final kissing balloon dilatation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Side branch stenting techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Left main disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Small coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Large coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute vessel closure or dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8955332\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/20/4426?source=related_link\">",
"      Management of left main coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=related_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_22_17771="General functioning";
var content_f17_22_17771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F54714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F54714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General Functioning Scale from the Family Assessment Device",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Planning family activities is difficult because we misunderstand each other.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In times of crisis we can turn to each other for support.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We cannot talk to each other about the sadness we feel.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Individuals are accepted for what they are.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We avoid discussing our fears and concerns.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We can express feelings to each other.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       There are lots of bad feelings in the family.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We feel accepted for what we are.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Making decisions is a problem for our family.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We are able to make decisions about how to solve problems.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We don't get along well together.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       We confide in each other.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein, NB, Baldwin, LM, Bishop, DS. The McMaster Family Assessment Device. Journal of Marital and Family Therapy 1983; 9:171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17771=[""].join("\n");
var outline_f17_22_17771=null;
var title_f17_22_17772="Classification of SPAH";
var content_f17_22_17772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of secondary pulmonary hypertension by mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoxic vasoconstriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypoventilation disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sleep apnea syndrome with obesity or pharyngeal obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neuromuscular diseases and damage to central respiratory center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Severe kyphoscoliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residence at high altitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased area of the pulmonary vascular bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction of large pulmonary arteries, most often pulmonary emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obstruction and obliteration of pulmonary arteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Collagen vascular diseases including scleroderma, CREST syndrome, systemic lupus erythematosus, and rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasculitis including granulomatosis with polyangiitis (Wegener's) and polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Miscellaneous - sarcoidosis, lymphangitic spread of carcinoma, pulmonary resection, parasitic or HIV infection, fibrotic reactions, acute interstitial pneumonitis (Hamman-Rich syndrome), intravenous drug abuse, hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Volume and pressure overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume overload due to shunts, most often atrial or ventricular septal defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pressure overload due to left atrial hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mitral stenosis and regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left ventricular systolic and diastolic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Constrictive pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pressure overload due to pulmonary venous obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary venoocclusive disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17772=[""].join("\n");
var outline_f17_22_17772=null;
var title_f17_22_17773="Fluvastatin CHD progression";
var content_f17_22_17773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluvastatin reduces progression of coronary artery disease in patients with low HDL cholesterol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 253px; background-image: url(data:image/gif;base64,R0lGODlhsAH9AMQAAP///zMA/wAAAP8AAO7u7qqqqjMzMxEREYiIiMzMzHd3d1VVVd3d3URERCIiIru7u5mZmWZmZgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACwAf0AAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqRwKtrq8qCQILq7WiAgO5urkCJAuvC7K0OggCCiiyBiIGAgm2z3C4u7q9I78FI8I7xccnydDgcdLTA9Ui19mzAMwJsgcFAg4AD7OyrggACcyt9q0EB65oAWxV4FcCBQIaABwWriGYcdPMAfh1Txs7d+sEPIigMd2BjBBGcCvhQOO3ic0Q/+ID6MyhSy4Qd0lEJ8JiM4zFIhxQxoCiPwiuDBAYCQChqwInDarM2PKl0ysxqfkSgK2mOmZIBXwEMBDfr5UCCIxgBiEngGINUGaVh/KgAHzsnsqtEpXX1Kr51MFLqFUEQrYJABoA+M9VBAAE9iXWihUlVaVvmc6dHKVuOcqYH73aLDGz58+gQ4seLZozLBXF8M2IS7o11ACwY8Oe+QpfahqsXeuWIkC2bNrYGlC9vbrZ7uNQevuefbfo29sD1Z11pYAARQfYmFEMqa9VAwbIwwtRvhw4U+IiSj4oxvAag3hM/310cIAAPWXi8/cg75t2Kwch3WYUQTRxtdlizrAkgP8yBPij34M58PdbcyI9l5Ba7FkjQEhjNUOPPPTZtyCEJNogYWzmVYjAYjtRNV0r1fn00T7xONNdQuCVqGMMJzK3oyoEKGDAkAY8AIhprvyoSjGv4KXkk1kUwwABVEJpZRaJIVDAlmJd6eUUgTX55ZhQIBSBAmjmSOaaSsCjJptwJvHATkQaGeedQ+x1FJ58BkHln30G2kOQRBYp6KE4MLknoozOICWgjUYKQ5ZbFtClpJjGEp2LmXZ6gploKvBmDAQIh2MJHLWygFiKDlOqd6N66pmbOVxz0ggNOMMRPgpgs5StI8oa2pyF2jkDYQZeSgJHTnJ0DLLICvuZngTR0OD/VtFWGKwITCZwrQjZSpvZn1XWAG1YJ5j1amTJtisCZ+KSeM19aiXw3XSHAXQAh2rRi0JneyAJcLxhrHvvNevOItamHxkc6wgD9xExwYpMHDDFkVish8YYF7HAil1wjIfIHQsh3AHdaEGyHSuXDEQCCDCURct00OwyHzbLkfPNNhSAJgLGbrFzNDwbAUFJrzQQNBZDv9F00S6gBcGUDCCgntCEPA01CwqohqqTUGW9tRDKllC2FVqzkfbYLDzwAANLzyw2234yYwBQD6M9N90/oCUUp1gPsjbfJghZgAHvgc303oTzgADKBnCUd2WnCTJ44yTQeFjIjGOeAwMRFPOO/xeXo1E65o/bsxVMnXt+g5BAFaN42G4IbPvtuJvmutW/JM557csFL/zwxAd/eqQMANQAUE2p7HTx0Edf/PGR+kxAWaQ/L/323AdAfaTkZg989+RP73rCgDs/fvnsl7d7PA4MFjftbfTYfvnfIypkmsaxvv7998vfoWAHoPTJ7X8AZJ8ABQWUOWllclRY4BLsl8DtSTBQYjlI89RXvwoG0HUicBvcbOCwErSKBEwSSwn/pT0P4u98dsNbDYCFnxH0yjmqgQeyaJiCCyaBgi40n+f81qDZueBcZwOAswCQvMehC4ksRGAQpedDPBkOcQZ8wbfchUJ+EMAB+QrLFsNFgv8qsmKK5DNjnB4nJMmZ64noGsG6bMOZwiwsjgCAlxTRKETPac4G8xoROvTFrxHskCr+OoEaiwBEPrrvfAhQQCFnUMJBvmJ17VqhIlvoSOgtkk0PMNRDONlJ4n1yTbIw4gE7WEpPuo4BBlhAqCA4hVOOp5Wu9By1skg/teGyj40jQKW49DtW/lJ4thwTLEOigLQU05fHRObuAMNLve0xmt5znZBEUMRnrqGRuEzml4DSKzf6z5jYnJDr/uhNNYCzleIcEwLuNr9efjOdj8TcYu4mAFryhpT4jOeViFhNugA0nQK10hV9d05o4hNFu4OcOQOHzocm1ErsZFrlHPrQbEL/UpJfuOgO3llKke6IAcOsVBKtWdGAYm5AYmroPTvqI8L5bAEOQNMCDrDBxV0zmib90TYR0xGZupOmNW1canxW0AgeFJtB3dFiWlFDinLUoiAcStdWytKruhSEYojqDUjaSbGCtYdPBepZw2DWGpDVkW1dawniOoO38pGu+umJARqgyq7OlKZ4FU+Y7kFCU93LbPRB4UCwoUkTBBYGdkXjY5GjEC1BYDCApMqt/NKK1S1FQ1mp6lzTeszJ7qZBXkvlG+94tgOszrUlMUCC4LhS07YgslO0rWuKSK6mqmCMeDTkVr4BlAYAt7ak/aVuW9MgzvR1BVAsgWtF8B55fCu6/3ncTHLDqU/TPFcFgVRGgaa7DI0AhRbhRetPS+s5ckHKWoYFDzpgig8GmGpViImveluK0LXC47uV2S48/evbf65Xue0l13/bmQbcBnG5pGnuZgCcHAGXtLvOZbDpkOrRYLqXqwY9MHflKj7+QtVzoUqxPwMs4gEH07saPoODXQhh0ujrTGmKsRlm7MEaj2YoJQlGSC1cVhCG0hhDbvGFUSccA4CsxF7t74sZUycdl4HHFfRxaCQcU6v+taNa3vKHofxlrDYOAklMQD2foF0lF7lxhjPh6DgY5RM3rjuRU0AEggxiFptYrUPcxwH4amUyYDmBYf5xn0P8Z/beAkmjSf8mpMfK4UQbNTQJHdyhAWhpL5emliOt9Ck6vTFQ62DTHzQFqXum4kKzItRIXbVPA7FLCrPZ1BEStaoHoRKVutoImtZ1KWQ9A6AsmtEVPrWwSUFsGQRGljm+NBOCHetRD6LWNWhsPvYxjKPBKr/fjqKfcYDq9jUb2X8Q5jCPjQIekiBE3KguAM5br205FtfkXvYozu3sAqxYBdj9xjdKcqYNtYuMEMM3paudsdw5/OF6PEOq2EXJvnARHrT4hqJydVxxJzvXDIdEuRWIBvY0s3/Hom06lJEMWaSlGPLAbsQ/nu+Qa0bfYxhqN2mQXnTA2xj0koU80uvxWyvb5o4Y+Qv/z/A4LSGkp1rULzpuNAwnnkrbZVS4iXDOCKWnEQ1TFcDmpD1BWANWEl7vnpa1Okk6Gx3kZ88Y179QAAQwIMWi+jUjzQ7mOQhs60gPg+EmrHciUDvudVhb2rkHYbip29dkHyvEJ+/wuTvt6Igvw92rZgBbv30/5Ai96EdPenIs3oJ3ULzlv5C6zpJ5pKWPvexJf3oqph7zfT8D7N5S4HHzwDKzD/7oax89ficc7rk3A+/62Xua/1740Jc98XOZeNyb2QzJSwjzCg/Z6Ht/+Kuvn/W/egbrYY/7LwD+96E/fWD6ffxSxr6o5ul5J1BP/esPfvtNeXvkX78MrWdxkWci//lXgOUQfmoDf3ZmBrsnO+jnAvhngKW3f8NjW5R3gbeDgFywfAzlaacmgetHgdIUViD4fSJoPGiQfcuDcm4HeyUYfSeYTw/xgjCogVxgfl4DFRv1fDQofDHYH2MQgT0oEzbIBSK0ZujmgkMofUUYQUs4ez+oTmawTzI0gG71hEwYeCGDhbEXhRDFdAnxN/U3bUAghE/ohUkVUlw4gU2IBQvVfJ/Hg2soemjYYTM4h3TYhlfARpHTTw94W3iYh1oIE4EYenWoZRnlgRFSiKanh5XBiBHhiFbAdknmA2a4hIcYhJBIhIMIBqGEhPakhJuYiSS4ibwgiVSgWqP0A5c4hP+kyFameIqd+AWwBG15Z4U00Io9+Ip3aIq8SAbYhot1FYsHOIszQ4y/OAaPR0zCKAO6SIPJuIWxGI0Fk1JQ5wLaRnU1wW3cpF9FJ4qQSI1Cg4yoOAW7JHY8p1n2BgA/dwztWG+ilXWsSI7GyDT0mHnAmFMKsFPCcY3QpXJWwXILInAjgl2jNY/TWI5N8IwvKI6shx8NAhRj2HEigHF50XnqkAwUeW8I6YsKOW33mHwA+BZMJZEpx1ord5EEqQwyh4Eu+ZIwGZMyOZM0WZM2eZM4eYFLUBhURQ/+CF6IJEgu8o7vSHQkNgpABjLsZgKV5CLauG2q0o3hdpSiMHE5SJX/OmJy/YiVQgWRcMiVrdF0TPWTYHkcYTd2D9IAolUgh2AAN7QEalkCbAl2kdR2d0AUWNEPCVEVCCcSA4GWJhAz+YA0AEJUXVYDsnCV7uYFeKmOrkBoXBSYf2lCzIAyOZIAhBkSXPaVyEBx56CO8SgGn/gHjRlaTMQMRtKX0+FMC6A4QdIKtnEMydMwDqIDClAfcgmaYFCa3wBLHaGaaHEOinN3JSEPkcRE09VcS8k1uHkXm0UGqtgHvBks8JAWqlkSeZMAv3AAV4mcDPIKKVNeFIEATSYWFAEQeAFGI5Aq6PmcWzCd+FGdkflufpgCxAkfI5A830kdJaAdsFmejoGe/yOgniLAnrp5BrU4S3ugKEdxEt+QLTSyRSdgNycwEJNEFpmjER+iRBuSITQBD3bioQfKmM7loAWJRxEqgIFZmbcILq1woQbXIW4DHxxRFurwoUUloqZZfoSnB/BZkeqgmgCRndvZnexYn5yVgxcxIirxFWpxDmyBQ/C4m0iWETtqkUKKpP35lieAnSTwWeXVDkz6Fk5KEzhlQ5GxmGWwjJayoFWalyPim6kZXF3Emq5pFPgQOoiBnQURphkqpsqgEiMhHNjwHl4zqCPaBT8qp/NZIXbKAnr6Rf3Up5LRIYCKQ4haqBSXqe5JGtP5mC2xKd1pdYBpQrQAFP8REgyQmb39eRNjuiIn0xiPoyyx6piuQJZR8KneEaq1IZmtAJg04nqoGg+qyqp/+g0q8Sotgg2zSgK1mhWvgKtXYB1uuZyYIang4QAyIxfYyo7bCgemIh26IWH7Mg+ciQrkGhL0MIZi0CARUAAcYa1luWVUIUxiNK8QspnVgq/5oa/nyq/XOmYAO7AEW7AGe7AIm7AKu7AM27AO+7AQG7ESO7EUW7EWe7EYm7Eau7Ec27Ee+7EgG7IiO7IkW7Ime7KBEAIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among patients with low HDL cholesterol concentrations (HDL-C &lt;35 mg/dL), those treated with fluvastatin had significantly less progression of coronary artery disease, as measured by minimum lumen diameter (MLD) change, compared to placebo patients (p = 0.0004). Among patients with higher HDL-C concentrations (&ge;35 mg/dL) fluvastatin had no significant effect on progression of coronary disease (p = 0.09). The difference between change in MLD in fluvastatin and placebo low-HDL-C patients was significantly greater than in higher-HDL-C patients (p = 0.01).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ballantyne, CM, Herd, JA, Ferlic, LL, et al, Circulation 1999; 99:736.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17773=[""].join("\n");
var outline_f17_22_17773=null;
var title_f17_22_17774="LV diastolic pressure volume relationship 1";
var content_f17_22_17774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular diastolic pressure/volume relationships",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left ventricular (LV) pressure/volume relationships at rest and during exercise at early-, mid-, and end-diastole are shown. The simultaneous measurements of LV diastolic pressure and volume define distensibility or compliance. In the normal individual with normal compliance (left panel), exercise causes a downward shift of the diastolic pressure/volume curve in early diastole, indicating an increase in LV distensibility; the increase in cardiac output occurs without an increase in LV diastolic pressure. In a patient with ischemia (middle panel), exercise causes a marked upward shift in the curve, indicating a reduction in LV distensibility, or diastolic dysfunction, and there is a significant increase in LV and pulmonary capillary wedge pressures as LV volume or cardiac output increases. This may result in the development of pulmonary congestion and respiratory symptoms. In the patient with a previous myocardial infarction and an LV scar (right panel), the early increase in diastolic distensibility with exercise is lost but there is no change in the pressure/volume curve in the absence of ischemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Carroll JD, Hess OM, Hirzel HO, et al, Circulation 1983; 68:59.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17774=[""].join("\n");
var outline_f17_22_17774=null;
var title_f17_22_17775="Rubella CRS epidemiology US";
var content_f17_22_17775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Number of reported cases of rubella and congenital rubella syndrome (CRS), by year, and chronology of rubella vaccination recommendations by the Advisory Committee on Immunization Practices - United States, 1966-2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 410px; background-image: url(data:image/gif;base64,R0lGODlhQwKaAeYAAP///wAAAACZZv+ZM4iIiP/Mmf+zZv/mzTMzM7u7uxEREe7u7kRERHd3d8zMzKqqqt3d3VVVVf+fQJmZmUCzjCIiIv/588Dm2WZmZv+/gP/z5v/Zs/+mTf/s2YDMs/+sWf/Tpv/fwP+5c//GjfD59mC/oKDZxiCmeRCfcODz7NDs4zCsg7Df0FC5lnDGqZDTvAAmGcDAwD+ZWQBMM7+ZP3+ZTAByTAA5Jn+mZgATDIC/mcDZwA+ZYu+ZNgCFWXCfXE+ZVs+/idDm1k+mcK+ZQo+ZSS+ZXD+mcj+sgIDGpgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABDApoBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQLSVAECCAoAQKAlRwUAijRo4QKAaYIIhBRQwRU6qUFKEiApAiSTaDEADlIAUEADRAUAinTp4RIgB4EGABgQoLICh4sLKp00MPFEAAgABl0KFFmzVgQMhB1gQWB3ldAAAsgKWCAiSI0KBkzqdw/53SzMkgJ1oAapsxyBgAAQSzZQNMvRgWLM0EaSfULWkzruOUQRH4xYsYr8xlEd5WHRu461eLd9WydTsoRsXTFR+rxof6dCECPAHAPsuUcjPYZBG09bkTgFfEvIEKJWoUqdLaiMKuXi5POSICUgFgEI6VbLOWARiQ9bhRNteyGbuHrCjTZM1FzpmrZ5f+kPmXAMaP3IagMqf26/Obw7+Qv/7/4PiXkIAAFqgNgQchaOCC1ChYkIMMRugMhANRKOGFyFgYkIaOtJYahiCywuE/IzISgAAoolhiiCxSsiI/LyZyYooCxNjijY3YmI+OhsyYIo84BtljSkAS4qOKJ1wg5P+SmxRZj5Np0Vgjii2kwOSVlUA5j5YeBuDCjx5iuU2XZJZp5plopqlmlx0SGQoJKBKSAgVT0qilmLrciYuDesJzJwsCrGAIC0fWiGc2fdrCp5ugfOnCIYUmeigtklLaZkR30skCpFJWOmksnsqyKKahoEgCp3Z+ak2ooF4KkZYXCHBCcmGq2iCirj6kpQcClKAInALYuiquOTLqSQsCmLAICgKoIOyt2Iz6KijMOquIps9Ow+ojeSWyWLe5KrItOlCqIAAKjHzpQbbSjMgmt6e91aN97uUEbrH4TuvJCwK0wAi//rILjbudQjIfcZDSa8i3CqMXbkNQliDAuovEKqj/wM8QnCq3JEEHwARhYYBSX+SVVUHJDNPkknXJPcwQlCcIoOQiwGKccSK8SmlnpzqnSEGPLiEGsiAi45WTxwqQFBUADA9CE3KQutyfJynE2Ui1NjfjX8491/lj1wL8XMhIDqA1tHQjI2ZYaxAw7IB588kotUJOAio2I9hmvYzGPxqstAIOGBZS2jpVcNZlTNubwHQALBB3y/nq6om6jvBKsd7JuFtrhzId1XYAClSFV0UVqH2yRolTxt3jUUfukJMrCLBpIyb0i7ky47oireScAHtqIxbfnjmxJhqrSfCPWC28Mbm3svvrnfDq6yMxW7s8Mc2LOLcgIJ9muHyI31Mk/53KPpL39cNkv8rzikRg1XBZ7dgJilY+Yjn62BPvcCOG0ZZWw/QAkrlmBYna3Q1/wFCfKtiHCN38LzH6ABLAIhErAiIwgfoT1+YIMQEFWCc0ANwSJ5D1Akko74K+UGAqGFiIBVRAXldBmPw2gbVIxGxmKOyFClHBQkIchWXg2wePqhYsSZAvhynMoNxIpQkDTuJ+SOTFuBaAnQC0BTVvacBpMMCyS/RwQJuQ2OUKGLYoSnEVktkOTw5WlKhMxQGTycQXEcKj2OEQEhU04y62xRkjdUwBQ1FACC0xxwRpomaUOKEeFZWIAgzgkZCMpCQnKUkDdMRwYwuaIGADOnlhov+QBtERoC42iRsuck+NpKQqV/lIS3pmMIMg213EMksvbo+OmuDVoyiBrPKdshbjksxUJmKZQDqAAFz0jSA1AUpsqKwiOeEORwghzfjEpCQn2R8mzicJKP7SUqr4HOiu2LkKTEAkAfCkLV0HDprA8iw56Q0hggOAGBblh8cRlyboBwkLdGAQdvsmMJUIuXE8UyicAYwgEgqa2oimLalb4iXyCIkPDOCfABigQMF5jWZqo2wEAEz/CEOYwyRmMUxrTOsuIT1IbOCRIRiEIjeqO4Ku1Bx1YahnttPQ/40mogAwzQYl8a5GcOCRBRiEHWnaqmjdUhsEaEvZgBNPnvwGnj//qSf8ipOUWg4pSwVrxEuROoheMhUWOzyFR62RgNNBtJoE+E41g8i0bOoTrBtjxFENMABXAkCXZ31FWk2xVnHUxxMripRYByCBEPQVoGUMrPNs+lV9uSisizgqCDTA2EGYC12S1Z5T2fkyQmI2ES/lgCAeSQhThXZ9lB2b8SKRgqIiwgISGMAGBJFbDShVZq9d4JqGS9ziGrc1Tw0lJUgQO1I2wpGqFQRfD1BWAZQwuEy0bCQkhoLfNQK3uh0EX2MqCMBiV7vQkwS/gPsI6BLCkUkVREDPyzv0NsJc1u1nbnc7CEeOwLPnom99B9wIEjArYO0dwAcK4Vi/AsC1Ai5t/3YdQacVePe7uaUuIQ7w2N/eMcK4ZGJRu2Q9R4ygw4Tg7AAIIbHrghiMIsasYiGhYg0XgrWDMO+LQ6yvSFGAAi6Y8SMygOJC5BajAIjVAXf8IEZF6mt5bUSNETHdQVQNtExWboztdIELeEDIjSCygwvBV/4KAsJZJshgvREWIYOZEY+0sSHgSwg6fTjNAFlzN9q8OdsyogDxRYR/WZxfPFdotqrgsINbamiB6Jkb6lM0IZTcaEcjOhUWwLEgiFjpDTFCnIih6wxdoWk/d5o1jKgAAlhmzy7aQ4FHxeibTy2+RUSliyCMICyqjJfT0rrWioBORZbZLda9GhYiCG+vo//861cPNa6CaIDhcj3qVtB52X1rNqoVUTaO9KbVun7FoLGtIm1vO9gugUnJwu0KSY8OueY+9oRZ4W6ZFjHe8ravKjK94tbeG98BvLQqNC2IpQI84PNmxVHlbOeDI1zfquC1II7o8OYIPBXJBgEhvFnxdzx6TLG4dnkn1vF4fPxAIR9ABgjhRGeAAMklv8/FUVHvJEeWGTWPOTNnfgoOL3gQFMW5gnXeiZPH9hT8LsRMkeHIfhN95wlnBcEf/G9lNP3pTeL5KSwqZ1My48ROx/o6IR7xATCcvcvga9jFniWtm4LIGh8EN5OhdjmzfRJGHy0sRP5XkjMjt2a/OyHdXgr/EKh8435fBiTtLniDEZ4UNa8dgpWx+Ma76PGj8Pmkb54MDpPV8kQ9BwQqINfwTHMQc71mXc9z11gQHHnK8PwAAg16bpljART5Dj3nWVWtVgefXpWtLKa+9GKMdfa1j0Te0SgyruhULJ/xH2V+itKCwoLr/mZG05GffNuTgwFcwQBXRCoY1BdGMMVWzFsYoNLK7jrwg6jeMqA7ABF03/vieGZFGPD8hUYfhNQnL0IFb7EAd3WGdsiQbGJ2f8m1DeInCPR0VfTUasAHNe4nbtw3cbKTdrNXZAwoUeXwgODxEd5xEaZnTetmHu13ga5geCuXY4mHDBblSGP2gTflDodV/3SzUHMcdwyP1AEDEF02CILpFQscJoQAIHmKt2JTN4TCR3ar8HqcZwycJQEA0IROGEuYRwqPZAFAFyix91hYmIV4sYWjgH2CgEjIIGm9RYYsKGGyIHFUZ3UD8F9y6IZlGHWtQGS0V0PHQGd36IYIcjrZgYLGlm8pR3sNhwx8CACBSIaDiDjgVm2w8FL2J3cbiAxVNl54aCSp5hJTQW3nZoRFRjmaGHh8h4cOgntCkX7sFgtAiIQ9SAxtmIqCOFQ+xBWiCGyzQHD8Mj0+2G+2CImLkADagXs5MYmyQAAEsAAMIBQYRAtd+IVLNgxJBwDDmIUEIh/aYYjhAwsvhB3qtP9HtSBxlHYMmgcADdaJWqgMjvMAksE4v7BmEqeGxeBuOSeIzKAAWtQA8pREtHBitFd8wGCJgpCPxLgMGFAR8AiNADkLfMcs9VMM14aQ2sgMRtGM3TGPtWCQmHhnwXBt18iOywcJBMCQosORtFBzi1gMZTYIY+iEJfkIqlYBD/CPOlQLsUgIpuiS8HeFa6eP7hgA8PgA8viQvRh2sxgMaAiU7JgWzFAB09EACrCCeWIL0ygIvxiMhBBrTzmTjtA9oPNOZ1SOP3mOxUBwjyiTrJAA/viNl+CWBECWZUkLnCgIaDkMOyleP6mKq6BFp7FqmsCMzuiQSCkLAjkI9igMNbf/lkO4LWBRlVsRAIZpCeEITdFIC3xHkL1Qcxn3laqgRchhEq42Ce8Yj7FxmLHwUg4mkRRZh++VgX6ZClrEMrWZCfxoRThZlztYZC0pDHyXjY+pCidpHwyASZiwkESJAJVJjjrZWR9ZDAbYX7IplKiAexAFR+NICUYxAQvQAKeXk1gZdmLkk3LmgqCpCguwnuzZCe2ZmdI4AL41cmMUDHJokcNJmx6SmpcgbC4Bn7MgcYw2DI80nwfpgQmJCoCJGvxpmSeDAArQnFdpC3dpc9X4C1OHnzY4RW3VAN/ZoNyZTkWBARKaC48mcnkJDCN5oD/XieMibAjwABEAoqa5nA0w/6MAKguO9IIAwGnDkI8xuaHEuX9bpAnMCZhWaaK3kI5nVnW/AKRBeZG0aTbMWZr9uZ0TOp5e2KQX9guGd4mEEKQfuC3eCQpb4RsIAJdKegtN+Zu/YItZOZu0SRIQ0ABqOgk+UU80uqa20IgaCJK8YItNaZ2nQBQPsAB8caeQ8I7RtqeodAseCQAtNgwVypeMx5a0aTgnyQCSYaRp2kFJ+qi2AIRWSJ+U2pfShapSqqA8YRIPIEOXIJbRoZK3UKAjt0vBsHCG4JhjSpxJkxELADJWOgkO0ABzGQwnd5cp6gtYmJguqp58wRU4+g0nN27L2gtYKJy9qgpvc4x2GiC5sP+OPRpgwbCXhaCtDAiW2pILKmZvjImg2Fidq7oM7ykJYLF/JkiC1HSCdKWC2nQLukp1XcoL4loIkUqoimASgiBqy8gXfWEJ+bR7N9F7FGgcweeJufCZAOCmgSqvAKCh6doIyikIyrioUaWok1ABDxqhluAVENB/vvF/DrUWEFV9N1gL6LmxCNgLwwiy94cgO3GSEDizk4BOoSoJjnOSC0CilXAy0XR+sER+JmUZKMV+rbekQSgIkwoM01kIPtt9BOI5Z+OKkQAyBCCj5ZcJp3mjjtoILjQBMKtTAFizAmhqtTCNS6kLj1iFJDlUhJgau+gI8sSoRsoWdhUJGJATSmH/F70ngRS7VRV4tWwaeDrmC2sppj8blmFRso5wFP43SJXAjJQwAacDjXBVeiTYr4drfbeQmNeqC3F6Y1Gan4xwNgz7CCFBEmeaCf7Yu/6IpZiQgzKnC6xpocEQk5gLtqswAR7aOGrbJW3LSLpAqhlFrr7QrojQhnJ6Ct1TF2l7Ca8avq8KutKrC23ImbaAn7yauZkKMl5hgZDGCy+JZrygvqpKu6cwGwhwkvA7Cb7bu8B7C8s3aAbXCzl7COurvKlwkhB6MuEZovuZo7awjhz7bqiRiIlQqfNqCgvKepggvuFLvgO1C0lHQqiSba/grIeArgqcCuw5rBB7qIcqwbaw/3BLOWuroMGxSXsbXArfmQDFSpeWcJLLebTlqwsZd8O+xgqOycLJty0nWTYPuwk1eZPRO8K78KXzNTZLvApeKWiwub0cHKNWdC+WcJpGecUcpQtHeK04PHCze6A1iL9jrEXvS8VTWZU0PJ5CICuGEGS4GIVx/LHwKqSpcK+lEwAPbAmyKsR8ugvjpUi1kyx5m2hZmwhfW3sv+hI32Qly6ciPrAsCeUKxIgCPssWvoKGZDHpTdLKewLzHuscd2VcGpwLMMj2vqwoFewgr2sOlYLScoJygs8hZugtV2HDMFSi/46N757FhOsjsiwpmK6LEXKMR8AAd9B2qmQu5NQTJov+z3ZV9GKwIyavJoblq6Ne/lGCTjSrLZokDE8NdJQYAXvcKyWZmiFDOrHzOjmMS1RwJ/gh+Aa3N4qlDHjI7BwioqbC+AZug3KvIq1sJjhPBtCpFXby1r7C+CWzOqiDD/ywJIDy+7kwpXVzJqBC7CHy/62ABBiABBvof2/LDQcwJUQXAIz0LOKyEsIC5G00OHQB4l6oeUKzIGaHGj4BOU7zNe9LFuXwKfLsIXdsOhgdJ+Kwf27ITRKFFIvwICRC+earUAtzFVwYLPuvE4WABRFZ/KgzT52zHRPkJCEDQvLlHgTyHqVzIO9wOHWBRA6Bx4wYgkEk6YPHRkVDTC2nUonL/vPKpCH7ICjv6Z85MDiGQWxKgYasMF5vsAJ28CUiNslhsuQNAXohQwajAwgeMDmD3AVtKyHMs1MzQ1a96TDcdkJENACbsCmuNCJedDRbA1/9FCL2cH+q6CDvRFiGB2E31C47FAattCCZdCEDIw5iQwLuNDZQt2s9sIMOdCGK5F4VY0b2gAZQd1FtpYpe8CdSN198QizDXlRdVINuNCNJmlCcBwwIsDHv9SHFXCE1dCHz90phwZIxwhOhgv0G9HPF9CDuxAETRjMhqjWktAs1dvRa0CPymbJpQzvqcDfh5z/CtDB38n+ANDFPNAe2NvoPgWI/Eo5mg4dDcDad9rrWt/xoEgqig6I2zEOJJXdB6eVQSgM+uyQgnZlFIeAlMuggbjg3C+ddWfdRtwbmu8MLr+eDGwNIrHp2MYFEqDuCVkMkoLQ7CWd0rsYrmJH1m/CTJ0HQf4FsUpwj8ZuVVXQnF2wg9nQ0erttDB9gi+91kO4rGMNmMZQHPrY5DF+OTYAEbMIOOUOfY4JjBLdR1XU8oEbhorgwacFQbMKCJ0IjUWwkdkAGAF9qLrtLfwKtJ3hQEMgHQyJy+B6u8mOb1198AELACHgkWAAJ8HYSb9QiMfg3aiwgNLdyLAEc3fruIiAykCnuIgL0AoLGOEAJpzVgZcOCJkNviIKa9PuZmuAtHFf8C6DvnAPClj5Bsj/QBGzDhCSbd4SCmzi7selgMJ5YB9GsIfgoAnc4IKjYC7S0JZo0N5grG6o7g2z69jEXaghDstb4IhtfakdDv1wCyj83W714MRyUDmXgIzC4IUZ0IFhXnk7DL4gCyYj7w/pDginBiNRCDBlt/K8/wgwCEA4DukzDy0mDoXpvnTT7xxACEKY+rhtDuAJDxtEKAM6/e3MDCp64SJg8KxM561bSvqat6/iq5ysABRDCFhJDwgxDsJ1xuXW7024D0Lx4XS/8JzBuzHCGxEPi4v2ex6gyVzpABNACGh3DvhFDvhxACb+wIT00Od64Ig+ra5+A4DhC3Muv/U3RL9ckQAj1QfOJuCOB+CBmw946Q9NOQwNlO8tPAAG0hteZXUulXtUdb9okgAcUH9IIg9MA9AJTfCJYvDQm88cxB+p6AezZh+Dxl5jRLGoIwgBf8DBlgBDvLW+99CFw/CC8VKQMLCa8fDb+eSgFP4+WAEYgTgXkxgZDr9oq/+BZ/Z/9eCCf224ZgUV0yeZLw/Os+9ja/GrQfzKiBEqebr+Ih9RH9hsrwAyofryzOYDgPCACCABoDAxYnAioAKigCJYORkpODBgMHlJmam5ydnp+ggoaeBwMGoaipqqusra6ZAa+ys7SdCAm1grG5vKw6AkmTlhuaFoYWkyMDIikC/yiDJgKPq5aYvdfYgx0DHKQDH9nh4uOtu+Tn6LTm6eMsAkeThhqbHwMhkxz20RSR0QImqqqxGwiq1ClPowgqXFhrHcOHDB1CpHVBgIx5g0p126RshKRSEgCUEOBB0gtpAFGJGEBsIkSDnxK6nElzksSaOHvdzJmqmQAQkQoMyMApxDdJGYYCSHRhUokAUKPulCS0AM+BIJR6qmftqleCU7+KDRV27CZp4Cqx5GTs0CALEgZ08AlLmt2ygqqaHafXk8C9gLHhDUwYwODCSwXQwAhAXqd69wRt4AZgX127Agb3RZxrM6ekVjmLZnV49NfShCkoBgrAaFpOQokKWgl0ZP9JSgEwZ/Yk1KPpWStbdvL8u/gm1MZrIgc8skjajt42Fhowj+nlu94OJmf1t1NWEdvD2xQfePleDwJqUAcAOeb6rKfoXpc2GCb5VN052b8f3jx/sPdFA8QAILSFjF9r5UOMZbBIBVV2/4USF2P6URZhcv5diE6GYlUkgymugRLbNhIgY1sn0azwSSmvabiJTAgN4GJxHM4YTo1eNcODIUn5pouD62ikjGzWcUKCNCl40paNL8oIyjFMioZjlLxMeRVahtgTSW6YORRXXJgcKcAnqqXUCYxUCrLNRp9wlWZhVr4pS5w5ORJElgfqoptDK1noDj+enNSCe3JmZEoo+RX/Khadiq7CaE2q7WCIdnp2KUlWA/jmAkmfyHemk4Xu54kyoTW6qKkLPUpTCwK8UE+plWIXyTbrAbCCACyAkkiuj12iaFayfUIcqjmpSqwnxrqEngchGEChYXtOIoJvYpIAyqaQdJIolcNuMhl4x16VbLiajAvRSdnaBOQm7qgISkUnINjVm91qIiq5NJmLryT6MlQRoJQkYkIiL2yyqQuoOLIIJ9tGGVwoa+6LU78SG8afCgLES4k7z0SjcSa38grKiZ8RqGjDTVacLycLMAAVAgsAAAECUE2gMrL/SZMJq7cJnEm1qKQ43ACwpomyJlDeDFFZEDCwwAIVEABABBEA//BAADErXe5/jiQpiU9eo/exJO2mIqbXmtRr44SoHK31OaUhILUCD+iCy9u4/adaU5JsOqggJDgiciQHq1ImbEQriqa8eKf6CQEI2K2LzY3zq/c/kwgeCXoARxKyKoJy8p3ioIJCauVgrTsJBjALQrfkqA9C8ULLSuKxJGLyHYk01vak8yb3RhkxKmrHLhgnM2MQCdVWY228Lv+hl64gqt0WyUidA1CRu6rsCvyhcgbfybfPb8jJBFJVIDPNAVD+/OwK/RuJT73Pj+TmAiC8CrbfU0ql+BXyX/myAT98FXAg27veNCgxkukdbhXw2sTw3gSsVJBogOQ4YLg0yI7fAf8gcALQnSQwJgC03Y8VCkuZnIqHtNJh8HgvdFSEeCeI22lCNfqLYCtIlonFMYmFPaxVDK/BQWIVER17E8StCqaJiqDAWtJzhdBaWKiH4cdXQyRiFlNxxHOoJlcYeyInblWSB7LibC3ME5XcpglLRGaLuehio+Q4jto1EEXOQKMrzCgMLBrNj6E4HRzjOEhQ0FEc6HGBmBbGiUSMZGysCF0m2BghtqUCiIUkSyZx9p8/nYR7x1FdKzzVx3lFyYeemIwANylDVh4nQtvzWSe4JCtXeI8SbpQTKjsBQFdq0pewiJCY8oisaL2Cf5QQJJUmiIpChASYpIFm3vgDpMHQkj7/r6gmVRKXpl5+SpqtBKfs/nPN3czSmOVAZ164+T/wqcKS4jRkPMdJTXWWy56qKKdDMHmfClIDkPPkxCHlNFDB4BM3oiSNPY2yShfxE5daCign51lQIh50HPr8iDuj9NBJdDSeFaVSSKt0UXFkNBLejJAVVfFRcY6USS9tSEI3NNOU/oeSmmCoRCcKUmAyKBLOfBNOM2HTncZ0RkcVDykHscsLwTMVQd2pQI/VAAYMIgEKCEAFHCAJrGqVqzOrmSBcFgDlvRKYRYpEUyO01m9K9aymgopVXSe1BkQuEgqoa+SYd7UFEKACC4DA67YGTB4yFaAzaisnnvpWyxGLAHN1/4DzErAOycaMsgAYbAASEIEGjFVqhPXlTwehDDbZiJkBQWxjoffYuWIWAJSFwFV3EdvNTo4BoGWAWYMJzKUCAC7snFFRNzGM1U4TVZAVhGVhW9nJxkKznPUsAHA7iBhoE5ppHYRR5BIKEDwrGwf47iyGm7bgGpe1yJ1rZvUKAMniIq8AsOvUqtbXvwZ2sLwtLKekdZRPJKWhvGDRNfzJit6c17FxjYpsvbpVACQXtlltcFjbN1ao7Da/ohVA9gQB3KJlQiiOEQeI1UiLlkpCpwemp9JuUSVp+lYyA5CAeCMxmW9oJRyWiGhnzJsK8vY0oEm9T3YjYQkAA6AUmQIJif97EZdM9WKlq5hOilX8Y2gaFqhxYc0kOhAX2dRDy9egVX9zMVQVTjnIF0KzeKLxN0pkRcaTsEA+PnCgyZi2F98JcS3KrIm4dGDKFgMyOJvxDE3UA1xvqQcH1BiXNz6ZQMXNBWNTa0rjqpmc4kxhJmjl6KRI4M9B2Sgv8tGB2PBCsZ2A8nkvTU1xsoqJH47xgZSB2OnM+BVS1sipXbgKA5/ZE1cbxITdZzxWb0eShl4GAGosHKTcOBeqFIUQZYHaVRjlmSnGC1kHwVfnvU+cYawQ0QzhYUOVqBegEUSkxytqVuTD0Zb2xGszWzfD3K3Y8dS0Jmj9bEq8qhduAoCpaeH/Y470e7WDmbdtDUNs1Bl7O69my5zHZ6FaLElNMa4FgV1BqyW/9bpdNQd0y/fw5CBbE6X2+CTi0mxZhGgQfi4xj1lRj5Y3NuHm6HbW8A1uZ9RCKEZWBXQGQRuZl3sVWWkRwjtBVgoPe4AlT46+cW0IUM8il4MYHXDWMou23HocICiA2MdOdjBHKerbQXtxIk6LpARLFknDOLZfwedUz5wcYs6S3g3ho7NLVO2/OfkrkKzyHlcc5tyVRd05YWeFKMMAZCc7rW3uIsDTaJ7h3vPdL3nwosti0q4AE0EaXV7VpvnvAe1aLRqveK7TWNlw5/Ur3D4Qo9x5Ep62OltAoHsp/6F+nqwy0ywU9PnEAxXVbq3FBdmxkr5noh7n5kQHFH15Qc8zij9vtwUzTol8VHr7t5cF8dHh9U5YoB503kQImux631s/njqkRVt6nwqt437zBdH+K+xPjskoHeVxgWjJYAgf8GaFtxeW9xsJaBon1HYHpxImQwnR5goF9wm21gkhYHY0137SxyNxlmO+kQ9HBxgLOBolKBp8RG16pgrelwlS5gobp3kaKAk1Bm+qMB0HOAnMNitfIhyTEX2ccYJBKFHYp3lv10xN1YKtYGKpdHhbliWL5grKIIDCYgiRgSkf0HsiaIK/N0/xR3ArGAoTmAnptoT41wrARX9q0mX54P98qfBuquBpB9AnIrBkP5iDp9GF89SAtGAJR2g6+PdyrKBqtdAjlHB+32ABSPZ9n3Bt3KF3MygIWziE7wdSM9UKF5gKAZcJBtIKiwcKjigJiBiFAFBarGCIq4CIn/Y9QEgYQogYrwgnJRWH+rcJnUgPOkZp2QCHkZB7bxEXI2iLMccKFlAAeGgJboiAeuhSswhVhsCIOTVm++ZkrAB6tDCFkUBrprRdash4TogNSPZ1XhGLrvh3zZgK/0U81Kh+0pgKyBdlSbOD/PV/2hKB4+CHsLiM4HRStDAd0AhRNhhnceeOspcLNXdkfMeJwBgKmTgO4Qgn+ihN/OiAQScJYfj/fLkIMd/IC0nHZQ+YdTEmjpHAf/f4kXlYiS4FJNMjC/64IhuZTCYZQOLQFnOWg0UGCuN3Dg9ZHhE5T/6wkq8AdFX4h0T1krxUi7XQJ+nHCRqQZZ5AInjICytBlEpSAN1oUj3pk9KwAvXzCsD1j0THgU0ikm4Wk7RwbVd5KSHZCbTHDg0JCqpIli2GklJ1AY7AlQ3iIEMTfitnfPVIeUMTjBqXlpNwaJ0gegORjhBIgFFJSHQpVY0AchOpkGIpCcs3lCx1hgrBaezIl+PQkqAgh3FRkXNJUSmmAvp0ASbgAZMZa54pCCRZIRwgl5FAiC4hFBIAjc23EIrZhGvhkVQJ/0OmmW17chfn+FsstwlJEYl9Nikb0JgA8InnUA/c4F2ieJHoMB1L6S2GoGXbJZiOOZwHpk8UQAGsuSeKtJeboIQF0ScxlgGEqW6mh1B6GQ4akAHsJwJvlHQPsX4x9o/ASYOGAJg6kZVGhU76JAArwEicmJOS8IKpYAEgkA+GwAEFsgnWiBvHOQsbkGMxNgIacJAPMX3d6YKjSQlJ4ZcEZKDmaCk/4iCOsF+aYGeRN3a9uQoHgJ9ZkgEB2RguBHLQ4qLnoAEFQKF4MhEWkKJ1KIrop3IrsYpY+Zgfd4mRQAKsAqSSuHdaCp5KsgHUyQ0F8Cxook8qcAEe4AKtSQ4h0P8nwUkQWKh7lgBnnNikUSqegAYKJjCR1TR2WMoKGjAC7GcALYFaCWqcQjoQFhAC0HkOHZAPEtASvmiLE3cjLHqnGtolHnABF0AC/NipVDo+7ikBIwAfVapPJ0ABLnCeXZKeqGIBOZYBmNKjltlllCqllnpPXZKrXfICmtqp6tSnQFWk1cQCV/qrQJIxgyMuogSs6pglBDoJSPYBBjCt1Fqt1lqtIvCsVDZEZHVhx3WrxdQlJUABt1KombEn5UkB+oQ2nlqfQWqo53qok3ABiZAZy5pQknmv7gqkviqkzEoJ/tmmEqilBFuwhiCqaYkXBPAyO6cy9iVY9YZh4CpQv7r/J+OqrsVJHxl7qv16F5qqqndxAh6QAv8KOJvSsdgkOwi6sv5qTL26J7x6AShrTi8qFbKjrzZbs1FxADx7ANXUs9X0DRugTWUhWVyFANJ1M531WXA1sQKFryzrsS/bJTEar/BqrmkaCqi5Jx7QteSZrvrUAl7LtS2AsV0CthmrsbpqtRpbnql5AYsws+Ygt1sStfSRJRlVFpAjCA92M9Q1Xd6KYE5LGjgbFSrromWKtehKAU+xoceRtubKtlaruGtbqBy7J2VrtlebtpIbAGh7tm67uJpLH+k6upnxuXeBBDIgA3nLCQ/2V1qztNMFWgBgXdV0u7ibu7q7u7zbu777/7vAG7zCO7zE67t7IhXHGxXJW7z6NAPOq08wEL0woE838Lx7MgM3ML17Ir365CDLq085EL36ZAM24AOdC69qe77pu76Uu7ldcruSsLcOpl4OC1gQ+0vfKrj4Ox4Sq79bElr82788FcD767+fMBU3IZkI+qkAHCsp+64PDME0S7cOTLOGUbgPUsHr8LYyuyea2sFd8sEcDMJSS8L0IcLHabQAgLRv062ogMANLE8CjF75+78zHGg33LQELMM1fMAxbMNbcon+IRH56q4XvK8YPLdUCsP8ArUt+8S1pKd2O8EburAB0DqbxMQ9PMBAvMMGTMNfjMNbPFU/7GABUDVjPP/EZQzGXWzACcA+ASBbXrytbRzGWjzHdJzHbHzEOcvHhquzGezHgSzISozERnxzazwV6pPIayzGdtzI5hEWO4EAEaAADavHjszDeLzHnJzJCxAAtHvDd7zJo1zHptzJkszIOVzKmCxVrMzGM/NXkMNVpAzJqjzGmdxeNNNgm5zLlqUADYfKmpAAvFzLt+zFEEBhOnzKuYzJr9zMwrzKxxzG0PzMrjzNg+Ayi5zGtizK3SwJERAV9NvKN9EAVVNV3EwJE6AADaAA98bMqezNk7CwCoAB7wzP32zMuPzM8ZzO+4zNSycLsRw1CEDL1Gw+tBDOcsVFlADM7RXHr/BXXEX/WcHcRQuAABPgABiwcI6zNC5BjoXCKNuMywg9Cw6wywatyYKAVVkjN66wsPeGPikNzeTwANvs0hExEQMF0gRV0jmt06uDxg52V60g0cxV0QyRzBEwAcR8yQNxSDs9uFy8oh4N1JGwAPiVzDOtCuvczvfcyeeg0VkVuE9t1VUt1ctM1Q8R1ZGAPkCStK1AzFsN1ulAWXOdDlD90WhNxhlk1mvt1wyBPnLc0X8N2Ht90OH502et2AoRFRUQzGW92Ix92JRd2ZZ92Zid2Zq92Zzd2Z792aAd2qI92oGBznz7MrRMAFnlWuyjCqZtxlfMVRUgFTbjwrXw2lZc0AAw21Ex/wHJHBWhLAu4jdqwxdvSZdu0MNyxXdxQ4Vm/DRXB7QrKrdvEHAAOPV0WxgvTPdGz7dDPDcomzT5mxWBgxT6Ug9yycNLZDWFftT5i9d3R7coBEFkBwFV7iz7uk8xkjSzzrVz1PdSRIFkQ8LD4lU39/dD2TdQPDQHJPNgyRd8JvsKedTUDbr8F7goLjeAAzsIU3uBVcuAqvLfwRVl+ZeEROycg/t8iLjUk7uG1MAGepcLwJV86R+An7gowruEzvlf0hTUuPmUPdjVcZVk4LQivrQpB/t/LNVbKI7t/OwtJPuTeBrgyExVCTQtR/tALwDoO0NROHt+skOWWxeVN/dxXLv8LYo414E1vX54Laf7JoEU3Zs4Ln+wAy4VZ0NXmuVDnd/5c9bZZc55ifavQWfXJWdXfDHDoCODgj6NehO5tD6AAsvW3ulULgw4VhS4Ike7gDgBflu7omI41b7zRUkPp+70Kl27doo4ApB7gng7loK7qfhXqD2Dqbh7rhW7FWRWxnQ7mrMAAnvVatXU37WPruQDszLXScbxwytxer25cfTsIqp1ZuCBYExABoMXqqRDtfKsAgxA1gqDnsD7P3i4I4C4JTz7u8evtr4PVDyDuaD7ODsbudePukZDuES3v0z4IRgvv8U7uAf7f2ezrqXDRZtXn9GY3/u4KBu/fl+XnsMP/tAfG7VglNRGgPBALOTHDwqhA8Z6u2llj45/eVR9vyXwb4+586yQ/Nyj/ACKP5eNc8ZnV8gSA8l9d1DH/6jNjVS8P8ysvbAjA8zY/C1hFbDs+X81T4vd143F93XQVXzye9DXv7DdvVAoGABu95hMmXQrtNC989VkPWlgdyuht4FAhW2EvCGN/VcYdR2AP3St96Me93rMgFWgP9+wdAMHe9urw9mvu1hGQNWVv9hCd9gAA+JfF97KQ9dlN3u6tzIPfCoxfVuwtYebN3HpP2pq/+Zzf+Z7/+aAf+qI/+qRf+qZ/+qif+qq/+qzf+q7/+rAf+7I/+7Rf+7Z/+7if+7q///u83/u+//vAH/zCP/zEX/zGf/zIn/zKv/zGQVkmH86nzvzSbyMbHQGUBVjTn/1vAjWqTjlWDN4KPd8QYOgu49Taf/6E4dZztbCeNduDHc4E8MlRYf7oX/9mMdu0HP5Q4fK8DQgBDQsBCgCHiImKi4yNjo+QkZKTlJWWl5iZmpucnZ6foKGio6SlowgBDocEARiIDoUArIOxpra3uLm6u7y9vr/AwcKJqKqrAcipEciotIbD0NHS09TV1tfY2drb3N3e3+Dh4uPk5ebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/AAMKHEiwoMGDCBMqXMiwocOHECNKnEixosWLGCszatzIsaPHjyBDihxJsqTJkyhTqlzJsqXLlzBjypxJs6bNmzhz6tzJ02AgADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      1969",
"     </strong>",
"     - First official recommendations are published for the use of rubella vaccine. Vaccination is recommended for children aged 1 year to puberty.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      <strong>",
"       1978",
"      </strong>",
"      - Recommendations for vaccination are expanded to include adolescents and certain adults, particularly females. Vaccination is recommended for adolescent or adult females and males in populations in colleges, certain places of employment (eg, hospitals), and military bases.",
"      <br>",
"       &Delta;",
"       <strong>",
"        1981",
"       </strong>",
"       - Recommendations place increased emphasis on vaccination of susceptible persons in training and educational settings (eg, universities or colleges) and military settings, and vaccination of workers in health care settings.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        <strong>",
"         1984",
"        </strong>",
"        - Recommendations are published for vaccination of workers in daycare centers, schools, colleges, companies, government offices, and industrial sites. Providers are encouraged to conduct prenatal testing and postpartum vaccination of susceptible women. Recommendations for vaccination are expanded to include susceptible persons who travel abroad.",
"        <br>",
"         &sect;",
"         <strong>",
"          1990",
"         </strong>",
"         - Recommendations include implementation of a new 2-dose schedule for measles-mumps-rubella vaccine.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Elimination of Rubella and Congenital Rubella Syndrome - United States, 1966-2004. MMWR 2005; 54:279.",
"       </li>",
"       <li>",
"        Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 11th ed. Atkinson, W, Wolfe, S, Hamborsky, J, McIntyre, L (Eds). Public Health Foundation, Washington DC 2009.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_22_17775=[""].join("\n");
var outline_f17_22_17775=null;
